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ABSTRACT 
 
The selective delivery of radionuclides to cancerous tissues remains a problematic issue. 
The lack of specificity and sensitivity for many therapeutic and diagnostic strategies 
limits their safety and efficacy by putting healthy organs and tissues at risk. This is 
especially true for lung tumors, which seem to have limited blood flow. Therefore, 
therapeutic and diagnostic strategies with high specificity are needed to overcome these 
limitations. Metastases are the main cause of patient deaths, accounting for 
approximately 90%. It is therefore imperative that a systemic targeting approach be 
developed that is specific to the tumor microenvironment rather than a single target. The 
specific aims of this dissertation were to: 1) develop radiolabeled gold nanoparticles 
(AuNPs) for tumor therapy and imaging, 2) develop a nose-only mouse nebulizer system 
for use with/within optical or radioisotope imaging equipment, and 3) test the theranostic 
nanoparticles and nebulizer system on a mouse lung tumor bearing model.  The first aim 
was performed by synthesizing I-125, Au-198, and As-211 AuNPs. The second aim 
utilized Solidworks 3D CAD software and employed 3D printing technology for 
fabrication. The third aim was performed with fluorescent Cy5.5 labeled nanoparticles 
designed to be used for diagnostic imaging. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
        The Theories of Carcinogenesis  
Without a deeper understanding of how cancer develops it will be difficult to pursue 
unique features of the tumor microenvironment in order to treat cancer. In other words, it 
is not easy to solve a problem until the problem is understood. As such, I will begin by 
discussing the different but highly related cancer etiologies (Clanton et al. 2015).  
 
1.1.1.       Inflammation 
Rudolf Virchow was a pioneer in cancer research during the mid-1800s when he 
hypothesized that cancer develops in areas of chronic inflammation. He proposed a 
hypothesis that cancer arose from inflammatory sites, which he based on his 
observations that inflammatory cells infiltrated solid tumors in a similar process to 
wound healing (Sanford 2005; Virchow 1865; Balkwill and Mantovani 2001; Landskron 
et al. 2014). While Virchow was in Germany, Louis Pasteur was in France developing 
the idea of bacteriology, which investigated the invasion of foreign pathogens and how 
they potentially contribute to disease (Smith 2012). Virchow had complex feelings about 
this concept. He didn’t believe that pathogens caused cancer because many individuals, 
with the same types of pathogens, were perfectly healthy compared to those that had 
cancer but he did believe that microbes could potentially produce substances that caused 
the inflammation leading to cancer. 
  2 
We now know that they were both correct. To show their connection, the hypoxia 
inducible factor 1 α (HIF-1α), which is responsible for hypoxia, also increases the 
survival of phagocytic cells in a hypoxic environment (Hong et al. 2014). It is also a key 
component of wound healing, infection, and tumor formation (Zinkernagel, Johnson, and 
Nizet 2007; Hong et al. 2014; Semenza 2002). It has also been shown to be induced by 
lipopolysaccharides or other compounds produced by bacteria (Werth et al. 2010). One 
key component of the papers mentioned above is that HIF-1α seems to be directly 
correlated to migration of not only immune cells but the cancer cells indicating some 
similarity between the two (Semenza 2002; Hong et al. 2014). 
 
1.1.2.       Mitochondrial Dysfunction 
Following Virchow, Warburg in 1924 hypothesized that mitochondrial dysfunction 
could lead to cell death or immortalization (Warburg 1956; Warburg 1924). The main 
evidence for this was the observed switch from aerobic to anaerobic respiration. He also 
noticed a significant increase in the production of reactive oxygen species (ROS) by 
cancer cells (inflammation)  (Wallace 2005b). Hypoxia and ROS seem to be deeply 
interconnected and studies suggest that hypoxia can induce oxidative stress via an over-
generation of ROS (Pialoux et al. 2009). Furthermore, hypoxia can result in 
mitochondrial dysfunction, leading to ROS production (Fearon et al. 2016; Weinberg et 
al. 2000). Mitochondrial dysfunction can be the result of an inadequate number of 
mitochondria, inability to provide necessary substrates, or a dysfunction in the electron 
transport chain and ATP-synthesis machinery (Nicolson 2014). This mitochondrial 
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uncoupling or the abrogation of ATP synthesis, has been shown to be in response to the 
mitochondria’s membrane potential, which has been shown to promote the Warburg 
effect, potentially contributing to chemoresistance (Samudio, Fiegl, and Andreeff 2009).  
 
To compensate for mitochondrial dysfunction three situations can occur, (1) fusion of 
partially dysfunctional mitochondria allowing functional components of damaged 
mitochondria to compensate for each other, (2) the generation of entirely new 
mitochondria by fission, and (3) mitophagy, which is the removal and complete 
degradation of dysfunctional mitochondrial (Nicolson 2014). Therefore, mitochondrial 
dysfunction brings about an alteration in the ratio of mitochondrial fission to fusion 
events, resulting an either an excess of long chain (i.e. MCF7) or clustered mitochondrial 
fragments (i.e. MDA-MB-231 and MDA-MB-436) (Zhao et al. 2013). This process is 
regulated by four proteins; mitochondrial fusion protein 1, mitochondrial fusion protein 
2, optic atrophy type 1, and dynamin-related protein 1. Dynamin-related protein 1 is of 
particular interest because it is involved in the fission process that leads to mitochondrial 
fragmentation. This fragmentation and expression of dynamin-related protein 1 have 
been shown to be 2.5 to 5-fold higher in MDA-MB-231 and MDA-MB-436 than in 
MCF7 and as such seems to contribute to a 10-fold higher migratory and invasive 
potential in these two MDA cell lines (Zhao, Zhou, and Li 2016). Silencing dynamin-
related protein 1 inhibits glioma cell proliferation and invasion via the RHOA/ROCK1 
pathway (Yin et al. 2016). 
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The quantity of mitochondrial fragmentation can be directly linked to the exacerbation 
of lamellipodia formation resulting in increased motility/protrusion, driving the 
metastatic potential of cancer cells (Rehman et al. 2012). Lamellipodia are the key 
features at the front leading edge of motile cells and are believed to be the key 
formations required force cell migration, thus they drive the metastatic potential of 
cancer cells (Zhao, Zhou, and Li 2016). Silencing dynamin-related protein 1 or 
overexpressing mitochondrial fusion protein one (presenting long chain in MCF7) 
inhibition of lamellipodia formation was shown to occur (Zhao, Zhou, and Li 2016). 
 
1.1.3.       Radiation Carcinogenesis and Genetics 
The theory of radiation carcinogenesis was brought about with the discovery of radiation 
and as a consequence of scientific curiosity. X-rays were first discovered by Wilhelm 
Röntgen in 1895 (Sansare, Khanna, and Karjodkar 2011). X-rays would almost 
immediately enter the medical field for dental radiographs and other cranial imaging 
procedures where there was indications of hair loss in patients and many individuals 
were obtaining hand burns and loss of skin due to excess exposure (Sansare, Khanna, 
and Karjodkar 2011). This brought about radiotherapy when a Viennese physician 
Leopold Freund, provided the first scientific proof of the biological effectiveness of X-
rays against tissue abnormalities such as a huge nervus pigmentosus pilosus (hair nerves) 
on the back of a 5-year old girl (Kogelnik 1998). It wasn’t until Hermann Joseph Muller 
in three experiments performed between 1926 and 1927 that it was demonstrated that X-
rays could cause genetic mutations and changes in the genome (Muller 1927). 
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Radiation carcinogenesis categorizes cell damage into two groups, the first being direct 
due to direct interactions of radiation with cell components and the second being indirect 
damage due to the ROS that is formed from radiation imparting energy to water, which 
then causes damage to the cell (Biaglow 1981). Double strand breaks (DSBs) and cluster 
damage are considered the main culprits behind carcinogenesis. Clustered DNA damage 
occurs when two or more lesions are formed within one or two helical turns of the DNA. 
Clustered Damage is made up of DSBs with base lesions or abasic sites, non-DSB 
clusters of base lesions, and abasic sites and single stand breaks (Eccles, O’Neill, and 
Lomax 2011). These impair the repair process and can cause genetic mutations that 
cause apoptosis or loss of growth control, propagating into cancer (Eccles, O’Neill, and 
Lomax 2011). Therefore, at the present, radiation biologists have continually 
emphasized that ROS are not the main culprit of mutagenesis. This is because ROS 
produce three orders of magnitude more single strand breaks (SSBs) than they do double 
strand breaks (Caldecott 2008). As such damage done by radiation, which has a 
significant amount of cluster damage and DSBs, is considered to have a higher risk of 
mutagenesis. DSBs also take up to an hour before a human cell will recognize them and 
begin the repair process. This would mean there is a significant amount of time for 
additional DSBs to form and inappropriate rejoining to occur. Thus is makes sense why 
the clonal theory of cancer development suggests that all cancers originate from the 
accumulation of genetic alterations in a single cell and how radiation promotes these 
alterations more than inflammation (Sąsiadek and Karpiński 2009). 
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1.1.4.       Cancer Stem Cells 
Over the past decade significant research has been placed into the separation and 
isolation of specific subsets of tumorigenic cells, most specifically cancer stem cells 
(CSCs), from solid tumors. These CSCs have one or a couple distinct cellular markers, 
such as membrane antigens representing their cluster of differentiation (CD), that 
separate them from non-tumorigenic cells (Al-Hajj et al. 2003; Bonnet and Dick 1997; 
Haraguchi et al. 2006; Olempska et al. 2007; Lapidot et al. 1994; O'Brien et al. 2007; 
Prince et al. 2007; Ricci-Vitiani et al. 2007; Schatton et al. 2008; Seigel et al. 2007; 
Singh et al. 2003; Singh et al. 2004; Wang et al. 2007; Zen et al. 2007). CSCs are like 
normal stem cells in their self-renewal capacity, unlimited proliferative potential, 
infrequent or slow replication cycles, and resistance to toxic xenobiotics as well as 
radiation. CSCs also share high DNA repair capacity and the ability to give rise to 
daughter cells that differentiate (Hadnagy et al. 2006; Hirschmann-Jax et al. 2004). 
Conversely, CSCs differ from stem cells in that they demonstrate dysregulated self-
renewal or differentiation programs and instead of new, healthy tissues can form new 
tumors instead (Hermann et al. 2007). Their daughter cells can also undergo cell cycle 
arrest at various stages of differentiation and have limited proliferative potential. 
Furthermore, even though these daughter cells make up the bulk of a tumor, represented 
by their rapid replication, they have a very limited metastatic potential (Bagley and 
Teicher 2009). Thus, CSCs appear to be the main culprit of metastasis (Hermann et al. 
2007). 
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1.1.5.       Cell Fusion 
More theories have recently been developed or re-defined by myself and other 
researchers to bring light to certain features unexplained by the cancer stem cell theory 
(Lu and Kang 2011; Zhou et al. 2015; Kemp, Wilkins, and Scolding 2014; Clanton et al. 
2015). For example, cell fusion as a mechanism of tumorigenesis was first postulated by 
Otto Aichel in the 1900s (Lu and Kang 2009).   
 
Cell fusion is one of the most underappreciated phenomena in the human body; being 
prevalent in a wide range of physiological and pathological conditions from fertilization, 
tissue development during embryogenesis, osteoclastogenesis, and during the repair of 
various tissues. Cell fusion can be split into two categories and classified as either 
homotypic or heterotypic (Lu and Kang 2011). Homotypic fusion is when two cells with 
the same end fate undergo fusion predominantly resulting in a stem cell with the same 
functions of the previous two. Heterotypic fusion is when two cells that are different 
undergo fusion resulting in either a heterokaryon (hybrid with two nuclei) or 
syncharyons (hybrid developed from nuclear fusion) (Lu and Kang 2011).  
 
The heterokaryons could potentially be associated with the multi-nucleated giant cells 
while the synkaryons would most likely be linked with those that have lost chromosomes 
(aneuploidy) and are rapidly dividing (Lu and Kang 2011). Early evidence dates backs to 
the late 60’s and early 70’s when scientists were labeling thymidines of circulating 
monocytes with tritium which were later found within the multi-nucleated giant cells 
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(MGCs) of inflammation induced lesions (Murch et al. 1982). Further evidence of cell 
fusion resulting in inflammatory MGCs was shown by Murch et. al. back in 1982 
(Murch et al. 1982).  
 
 Inflammation seems to be one of the key triggers in cell fusion, to exemplify this one 
study was capable of showing that the fusion process was amplified in response to 
irradiation but then subsequently inhibited through the administration of the anti-
inflammatory corticosteroid prednisolone (Kemp, Wilkins, and Scolding 2014). As 
another example, the only known environmental risk factor for glioblastomas is ionizing 
radiation (Chandana et al. 2008; Braganza et al. 2012). As such, radiation is specifically 
known for inducing cell fusion on the blood brain barrier and at rates drastically higher 
than the amounts that would occur normally without exposure (Espejel, Romero, and 
Alvarez-Buylla 2009; Wiersema et al. 2008). If we look at melanin and neuromelanin as 
radioprotectants, or substances that prevent the inflammation and damage that would 
potentially result in increased cell fusion, then it begins to make since why the incidence 
of glioblastomas in the Caucasian population is approximately double the incidence of 
the African American population (DeAngelis 2001). 
 
1.1.6.       Aneuploidy and Chromosome Instability 
Aichel believed that the spontaneous fusion between somatic cells could lead to 
chromosomal abnormalities, which could propagate into cancer development. As such, 
aneuploidy, which is characterized as the presence of an abnormal number of 
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chromosomes in a cell, is present in virtually all solid tumors (Li et al. 2000). Cell fusion 
does not initially generate aneuploidy, but it does lead to tetraploidy, which has been 
shown to precede aneuploidy in both clinical and experimental models of cancer (Lu and 
Kang 2011; Heselmeyer et al. 1996; Fujiwara et al. 2005). Furthermore, the metastatic 
potential of a tumor cell population has also been linked to cell fusion by the 
enhancement of ploidy levels and chromosome duplications (Larizza and Schirrmacher 
1984). There have been many studies purporting evidence of in-vivo cell fusion 
occurring between tumor cells and normal host cells (Larizza and Schirrmacher 1984). 
Even though the concept is dated, examples of how bone marrow-derived cells 
(BMDCs) are affecting the tumor population are continuing to arise, especially as 
therapeutic methods utilizing stem cells increase (Luo et al. 2014; Karnoub et al. 2007; 
Amariglio et al. 2009; Erdo et al. 2003).  
 
What is very interesting is that even though cell fusion is a well-accepted and 
documented occurrence in normal tissues, it seems to be relatively ignored until recently 
in cancer research. As an example, there was a very interesting proof-of-concept by 
Zhou and his colleagues demonstrating that the fusion of cytogenetically stable cells can 
connect to oncogenesis and tumor development (Zhou et al. 2015). In Zhou’s study, non-
transformed rat intestinal epithelial cells were fused resulting in hybrid cells with an 
unstable aneuploid karyotype and elevated rates of DNA damage (Zhou et al. 2015). 
Furthermore, a population of the hybrid cells were highly tumorigenic in mice, forming a 
tumor after the injection of only 200 cells (Zhou et al. 2015). 
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1.1.7.       De-differentiation and Trans-differentiation 
To add on to what Otto Aichel first postulated, it should be emphasized that many 
variations of cell fusion can occur that could possibly contribute to the formation of a 
diverse array of heterogenic neoplastic cells. This may occur within the same tumor as 
well, creating opportunities for CSC populations with different CD markers to develop, 
making isolation and treatment of CSCs very arduous if based on these markers alone. 
The fusion of bone marrow derived cells (BMDCs) with Purkinje neurons, 
cardiomyomycytes, and hepatocytes with evidence that trans-differentiation has been 
shown to occur, with no evidence of trans-differentiation without fusion (Chen et al. 
2011; Alvarez-Dolado et al. 2003).  
 
Trans-differentiation is a key characteristic of many tumors (Shekhani et al. 2013; Han 
et al. 2014). Since cell fusion occurs first upon the epithelial and endothelial tissues such 
as the vascular tissue, brain, skin, lungs, and intestines then this may provide evidence 
for their involvement of cancer development in these tissues (Silk et al. 2013; Jiang et al. 
2004; Okamoto et al. 2002; Theise et al. 2000; Weimann, Charlton, et al. 2003; 
Johansson et al. 2008; Weimann, Johansson, et al. 2003). 
 
Many researchers attributed the apparent plasticity of bone marrow derived stem cells to 
produce new liver cells, cardiomycytes, and neurons to be trans-differentiation 
(conversion of one cell type to another), however new finding are suggesting cell fusion 
to be the reason of why cancer cells undergo trans-differentiation (Alvarez-Dolado et al. 
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2003). The most significant evidence of this is the fusion of somatic cells from different 
species of mammalians (Croce 1976; Nowak-Imialek et al. 2010; Wang et al. 1998; 
Kemp et al. 2011). During development and tissue repair the fusion of whole cells or 
vesicle transfer of DNA between cells, each cell from different origins, is an important 
physiological process (Bjerkvig et al. 2005). As previously mentioned, Purkinje neurons, 
cardiomyomycytes, and hepatocytes have been shown to undergo fusion with BMDCs 
with evidence that trans-differentiation occurring in these fused cells, which is a key 
characteristic of cancer cells (Chen et al. 2011; Shekhani et al. 2013; Han et al. 2014). 
Furthermore, experiments by Ying et al. and Terada et al. both showed that in situations 
where trans-differentiation was assessed that there was also evidence that cell fusion was 
occurring (Ying et al. 2002; Wurmser and Gage 2002; Terada et al. 2002). When this is 
taken into consideration, it makes the authors question how mouse embryos can be 
injected with teratocarcinoma cells of other another mouse and create chimeras with 
variable fur color and cancer rate dependent on the amount of teratocarinoma cells 
injected (Illmensee and Mintz 1976; McBurney 1977; Papaioannou et al. 1978; 
Papaioannou et al. 1975). 
 
Since embryonic stem cells are explicitly known for cell fusion, this should make the 
scientific community question whether the bone marrow derived cells can result in 
similar characteristics. To elaborate on this concept, teratomas, which are considered 
encapsulated tumors made up of different tissues or organs, are made from embryonic 
stem cells that didn’t initially undergo differentiation during embryogenesis. As such 
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they share many similarities with tumor populations that most individuals have heard of. 
For example, the transplantation of undifferentiated murine embryonic stem cells into 
the heart can potentially result in them becoming active or beginning to develop into 
different tissues, with significant heterogeneity (Nussbaum et al. 2007). Teratomas are 
also usually benign but can also be metastatic (malignant) as well. Typical cancers can 
also be placed into two categories; either primary tumors (benign or malignant) or 
secondary tumors (always malignant) with both categories being well known for their 
heterogeneity in the neoplastic compartment (Lathia et al. 2011). These two categories 
are easily distinguished when looking at the brain. Primary brain tumors are tumors that 
begin in the brain and make up only 2% of all adult cancers in the United States 
(Chandana et al. 2008). Secondary brain tumors, also known as metastatic tumors, begin 
as cancers in other regions of the body (DeAngelis 2001; Yamamori et al. 2012). The 
previously mentioned MGCs are also sometimes found in Glioblastomas as well (Kozak 
and Moody 2009).  
 
1.1.8.       Potential Microbial Contribution 
Considering many of the epithelial surfaces are where microbes thrive, it would be 
erroneous to ignore what potential effects they could have in cell fusion or in the 
complete differentiation of fused cells, which some microbes may induce directly but the 
main evidence points toward inflammation (Kespichayawattana et al. 2000; Johansson et 
al. 2008; Yamada et al. 2004; Verschoor et al. 1990). This is interesting and alarming 
since bacterial translocation to the blood occurs through various methods such as bug 
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bites, oral cavities, antibiotics, superficial wounds, and even chemotherapeutics can 
disrupt the gut barriers (McLaughlin et al. 2002; Swank and Deitch 1996; Gendron, 
Grenier, and Maheu-Robert 2000; Amar et al. 2011; Nakayama, Itoh, and Takahashi 
1997; Berg 1983). Therefore, it is not surprising that the effects of bacteria continue in 
the microenvironment of the tumor as well. This may be either good or bad depending 
on the balance of bacteria and the type of bacteria within and around the tumor (Zhang 
2014; Iida et al. 2013; Lokody 2014; Viaud et al. 2013; Yan et al. 2007; Boleij et al. 
2012; Trinchieri 2013). Tumors, circulating tumor cells (CTCs), and metastasized 
tumors are all microenvironments in which certain bacteria can survive and thrive due to 
the growth factors that are produced and local immunosuppression (Morrissey, 
O'Sullivan, and Tangney 2010). This was clearly shown in a study performed by Yu, 
which found that bacteria could be injected straight into the blood stream, without any 
modification to make them specific to the cancer (Yu et al. 2004). In fact, they were 
highly effective at using light-emitting bacteria to see the preferred target neoplasms (Yu 
et al. 2004). Consequently, bacteria can be used for neoplasm targeting, a strategy that 
was first being investigated over 150 years ago when doctors were noticing shrinkage in 
tumor volume after purposeful infection with bacteria (Pawelek, Low, and Bermudes 
2003). 
 
1.1.9.       Fusion/Adhesion Molecules 
Considering Virchow’s observations of the infiltrative inflammatory cells into 
neoplasms, it’s no wonder that fusion of macrophages with tumor cells could potentially 
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take place and lead to the expression of macrophage antigens by tumor cells (Lazova, 
Chakraborty, and Pawelek 2011; Powell et al. 2011; Shabo and Svanvik 2011). Even the 
variant of the glycoprotein cell differentiation marker 44 (CD44v) that is proposed to be 
involved in some metastatic tumors is also transiently expressed by B and T 
lymphocytes and macrophages after antigenic stimulation (Arch et al. 1992). Thus, it 
cannot be ignored that CD44 is also an adhesion molecule used for macrophage fusion 
and when inhibited or blocked with antibodies prevents metastasis and repopulation, but 
not completely (Avin, Haimovich, and Hollander 2004; Cui et al. 2006; Guo et al. 1994; 
Orian-Rousseau 2010; Quere et al. 2011; Seiter et al. 1993; Sterling, Saginario, and 
Vignery 1998; Jin et al. 2006).  
 
This is most likely because of the profuse and diverse amount of fusogens, or integral 
membrane proteins that enable cell fusion, that are present on cancer stem cell 
populations. Interestingly, many of the so called human fusogens have been contested 
and shown to be merely adhesion proteins that bring the cells closer together, making the 
fusion process easier (Noubissi et al. 2015). This would make looking for variants of CD 
markers an important consideration, as variants of CD markers exist in other cancers as 
well (Emlet et al. 2014; Kemper et al. 2010; Ferrandina et al. 2008).  
 
Furthermore, CD47 is another fusogenic protein expressed by macrophages that has 
been found to be an adverse prognostic factor on human acute myeloid leukemia stem 
cells, the same cancer stem cells that also express the previously mentioned CD44 
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(Majeti et al. 2009; Quere et al. 2011; Chen and Olson 2005; Bjerkvig et al. 2005). 
Therefore, multiple variants or the expression of certain CD markers may propagate or 
progressively enhance the invasiveness of cancer stem cells when they are present 
together. 
 
Another receptor is the P2Z/P2X7 receptor, whose expression level has been directly 
correlated to the amount of spontaneous cell fusion occurring in macrophage cultures, 
while also being highly expressed by primary bone tumors; as well as neuroblastoma, 
breast, and prostate cancers (Chiozzi et al. 1997; Adinolfi, Amoroso, and Giuliani 2012). 
Another important marker is the tetraspanin family protein, CD9, the only protein that 
has been shown to be indispensable in sperm-egg fusion, while also being a cancer stem 
cell marker for various cancers (Ghani et al. 2011; Nishida et al. 2009; Chen and Olson 
2005; Wang and Han 2015; Kawashima et al. 2002; Kischel et al. 2012; Rappa et al. 
2015). To add to the diversity of fusogenic substances, interleukin-4 (IL-4), PTPNS1 
(also known as the macrophage fusion receptor, MFR), Chemokine Receptor type 4 
(CXCR4, receptor and ligand), and stromal cell-derived factor 1 (SDF1) have also been 
linked to the cell fusion process and with cancer stem cells as well (Bjerkvig et al. 2005; 
Rempel et al. 2000; Kucia et al. 2005; Gelmini et al. 2008; Teicher and Fricker 2010). 
The expression of both SDF1 and CXCR4 are actually directly correlated with 
increasing tumor grade and angiogenic potential in human glioblastoma (Rempel et al. 
2000).  
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1.1.10.       Tunneling Nanotubes 
Even though cell fusion has been shown to occur in various degrees between immune 
cells, stem cells, and normal cells, the exact mechanism is not fully known, especially 
since there doesn’t seem to be any involvement by α- helical bundles (the core 
components of fusogen soluble NSF attachment protein receptors (SNAREs) and Class I 
viral fusion proteins) (Chen and Olson 2005). This is where I believe tunneling 
nanotubes, which are normally made up of F-actin bundles, sometimes microtubules, 
that allow for the creation of membrane channels utilized for cell-to-cell communication 
and transfer of organelles (like mitochondria), Golgi vesicles, and even DNA to 
neighboring and distant cells become of importance (Gerdes, Bukoreshtliev, and Barroso 
2007; Lou, Fujisawa, Barlas, et al. 2012; Wang and Gerdes 2015; Bukoreshtliev et al. 
2009). TNTs have also been referred to in the literature as membrane nanotubes, 
intercellular bridges, epithelial bridges, or cytoplasmic extensions (Lou, Fujisawa, 
Barlas, et al. 2012). They have been found to extensively form in many cancers (Lou, 
Fujisawa, Barlas, et al. 2012; Lou, Fujisawa, Morozov, et al. 2012). The potential 
importance of tunneling nanotubes in cell fusion can be seen with the osteoclasts, which 
are multinucleated cells formed by the cellular fusion of hematopoietic stem cell derived 
osteoclast precursors; but only after the formation of abundant amounts of TNTs (Kukita 
et al. 2015).  
 
This makes the formation of TNTs a viable mechanism for how membrane fusion or 
fusion pores occur before complete cell fusion. This is corroborated by how 
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constitutively active Drac, which controls actin polymerization, or loss of function of 
Kette, which regulates actin dynamics and F-actin organization (processes that both 
regulate TNT formation), each block the late stage formation of fusion pores during 
myoblast fusion (Chen and Olson 2005; Bogdan and Klambt 2003). Furthermore, virus-
induced cell-cell fusion has been blocked by perturbation of the actin cytoskeleton by 
expression of dominant negative Rac GTPase (Chen and Olson 2005; Pontow et al. 
2004).  
 
TNTs may be the main contributor or first step in the cell fusion process, while also 
providing a route for the transfer of mitochondria, DNA, and protein when there is 
dysfunction, damage, or deficiency. This is a very unsettling as it could potentially mean 
that substances can be transferred to neoplasms that could make them more resistant to 
the drugs used against it. This was explicitly seen in a study that found TNTs to be a 
novel means of transferring drug resistance via the functional intercellular transfer of P-
glycoprotein, ATP Binding Cassette Subfamily B Member 1 (ABCB1), also known as 
multidrug resistance protein 1 (MDR1) (Ambudkar et al. 2005). The signals received 
may also invoke complete repair of the cell via nuclear fusion. However, this leaves the 
question of why nuclear fusion and not apoptosis with subsequent replacement? This 
may be that localized apoptosis would result in tissue instability/function or that the 
fusion process may be necessary to reconstitute the tissue stem cell population. What is 
also interesting is that 41% of malignant melanomas and 21% of lung cancers (50% 
being of small cell carcinoma origin) metastasize to the brain and that those metastatic 
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cell populations express macrophage-specific antigens (Ruff and Pert 1984; Pawelek 
2007). A combination of the previously mentioned CD markers, cytokines, chemokines, 
and fusogens with these TNTs would drastically enhance the facilitation of cell fusion. 
They are also potential contributors to the specific niches that cancer cells preferentially 
metastasize to or invade. 
 
This means that TNTs, filopodia, and lamellipodia must be collectively considered when 
talking about cancer stem cell fusion, invasion, and metastasis. A study by Nickolay et al 
back in 2009 corroborated this when he found that selective elimination of filopodia 
from PC12 cells blocked TNT formation with only weak effects on the stability of 
already existing TNTs (Bukoreshtliev et al. 2009). This would seem to imply that either 
the processes regulating filopodia also regulate the formation of TNTs or that there is a 
complex relationship between the two. I suggest that the TNTs provide the network for 
travel or the communication of where the cells should travel while the filopodia and 
lamellipodia allow for invasion and locomotion. The real importance of the study 
presented by Nickolay et al is that elimination of the filopodia by the CytoB did not 
cause a statistical difference in the phagocytic uptake of cellular debris, demonstrating 
that filopodia are not a sole cause (Bukoreshtliev et al. 2009). Jay et al. showed that the 
formation of the previously mentioned foreign body giant cells are preceded by 
lamellipodia formation, where Rac activation controlled not only lamellipodial 
formation but the fusion process as well (Jay et al. 2007). However, inhibitors of Rac 
activation also only prevent cell fusion, not phagocytosis (Jay et al. 2007). 
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1.1.11.        Hypoxia 
Continuing with fusogens and tunneling nanotubes we should also consider hypoxia. Not 
much research has been successfully made into why the hypoxic regions are occurring 
besides the fact that proliferation may induce stress that causes the vasculature to 
collapse. The problems this author has with these theories are that they don’t explain 
how cysts and other growths, such as moles, can undergo active proliferation with 
increased blood flow instead of hypoxia. However, activation of HIF-1α is a general 
phenomenon associated the hypoxic regions of neoplasms, while also being induced by 
lipopolysaccharides or other compounds produced by bacteria (Werth et al. 2010). This 
is because HIF-1α is associated with the host’s innate immune functions to help the 
specialized phagocytic cells function in the hypoxic microenvironments of infected 
tissues (Zinkernagel, Johnson, and Nizet 2007).  
 
Since another consequence of induced HIF-1α is increased metastasis and invasion, the 
degree of fusogenic (expression of fusogens and facilitation of fusion)/phagocytotic (cell 
engulfment but predominantly for degradation) ability of CSCs would be directly 
proportional to invasiveness along with survival (Jing et al. 2012; Lu and Kang 2011). 
To emphasize these two phenomena and their complex interplay, macrophages will 
undergo cell fusion when they are unable to phagocytize, resulting in foreign body giant 
cell formation (Jay et al. 2010). This process has been shown to require matrix 
metalloproteinase (MMP)-9, a highly expressed substance in a variety of cancers that is 
also believed to contribute significantly to invasion (MacLauchlan et al. 2009; Chen et 
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al. 2013; Duffy et al. 2000). Considering the pro-survival responses of many cancer cells 
and the high prevalence of macrophage antigens on cancer stem cells this leaves a very 
concerning dilemma. Could the body’s own immune system be contributing to cancer 
formation via cell fusion and as such can immune cells transfer invasion properties and 
survival mechanisms to hypoxic environments? 
 
 As previously mentioned, the expression of both SDF1 and CXCR4 are actually 
increased with increasing tumor grade as well as angiogenesis in human glioblastoma 
(Rempel et al. 2000). HIF-1α actually enhances expression of SDF1, which then 
increases the adhesion, migration, and homing of circulating CXCR4 positive progenitor 
cells to ischemic tissues (Ceradini et al. 2004). 
 
Apoptosis has also been shown to be a contributor to cancer cell fusion and breast cancer 
metastasis (Noubissi et al. 2015). This was corroborated with astrocytes requiring p53 
activations to induce TNT development (Wang, Cui, et al. 2011). Even more 
interestingly, hypoxia was what was shown to induce the apoptosis that enhanced the 
fusion of breast cancer cell lines with mesenchymal stem cells (MSCs), resulting in 
hybrids with an enhanced migratory capacity (Noubissi et al. 2015). Considering that 
Fas has been shown to stimulate the formation of nanotubes between T lymphocytes 
during extrinsic apoptotic death, this would seem to also suggest a link between hypoxia 
and TNT formation (Arkwright et al. 2010; Luchetti et al. 2012). The hybrid cells or 
those that underwent cell fusion, were shown to have the motility representative of the 
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MSCs but the T47D breast cancer cell lines themselves did not (Noubissi et al. 2015). As 
such, this is especially troublesome as these breast cancer cells in question were non-
metastatic until fusion occurred with the MSCs (Noubissi et al. 2015). Cell fusion has 
found to more predominately occur in hypoxic regions rather than normoxic regions; this 
can be explicitly shown by how the adhesion protein found to promote the fusion of 
hematopoietic progenitor cells with cardiomyocytes, vascular cell adhesion molecule 
(VCAM-1) is up-regulated in hypoxic environments (Noubissi et al. 2015).  
 
Therefore, hypoxia seems to be either a very beneficial or detrimental situation 
depending on the outcome. Either hypoxia occurs and the body can control the growth of 
the tumor and fused cells become stable or conversely hypoxia results in cell fusion 
leading to some combination of increased metastatic ability, invasiveness, or stem-ness 
in an area that is about to up-regulate blood flow due to unchecked angiogenic gene 
expressions in response to the hypoxia. By increasing our understanding of this 
phenomenon, we can then begin to develop treatments that use stem cells to cause 
differentiation in a tissue by making them without invasive genes and with proper 
signals for cell death. 
 
1.1.12.        Reactive Oxygen Species and Aldehydes 
The indirect reactions of ionizing radiation interacting with water have the ability to 
produce (ROS) in biological systems (Riley 1994). A common characteristic of these 
reactions is that the body responds to ROS by perceiving it as a threat and causing more 
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inflammation, often due to the mitochondria or senescence-associated secretory 
phenotype (SASP), in the affected tissues (Azzam, de Toledo, and Little 2003; Leach et 
al. 2001; Yamamori et al. 2012). This increase is believed to be the foundation of why 
the bystander effect occurs after radiation treatments at a single tumor site (Shao et al. 
2003; Chen, Zhao, et al. 2009). 
 
The propagation of these radiation-induced, mitochondria-dependent responses by the 
cells, and the immune system could propagate into a hazardous situation where a large 
concentration of ROS, reactive nitrogen oxide species (RNOS), and aldehydes are 
situated within a localized area. Even though acute amounts of ROS are used every day 
for beneficial activities such as inducing stem cell differentiation, chronic exposures to 
ROS have never been associated with a beneficial outcome. This phenomenon is referred 
to as the ROS paradox in which ROS is an essential biomolecule utilized in the 
regulation of cellular functions and as toxic by-products of metabolism (Thannickal and 
Fanburg 2000). The only difference appears to be in the ROS concentrations, where the 
ROS occur, and what by-products are formed by the ROS (Thannickal and Fanburg 
2000). 
 
The downstream effects of oxidative stressors and their mutagenic capacities need to be 
taken into consideration as well. The primary targets of oxidative stressors are DNA, 
proteins, and lipids. Free radicals also have a tendency of directly attacking 
polyunsaturated fatty acids in the membrane and resulting in a process known as lipid 
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peroxidation (Cabiscol, Tamarit, and Ros 2000). The most chemoresistant cancer cells 
have already been linked to mitochondrial uncoupling and preferential oxidation of fatty 
acids (Samudio, Fiegl, and Andreeff 2009). A primary effect of lipid peroxidation is a 
decrease in the cell’s membrane fluidity, which alters the cell’s membrane properties and 
bound proteins (Samudio, Fiegl, and Andreeff 2009). As a result, the cell’s ability to 
receive paracrine signals becomes limited. This effect acts as an amplifier to free radical 
production and lipid peroxidation that will result in larger concentrations of aldehyde by-
products (Samudio, Fiegl, and Andreeff 2009). 
 
Aldehydes are extremely reactive, have long lives (~9 minutes), and can diffuse out from 
their site of origin and preferentially attack distant sites with high lipid and DNA 
specificity (Cabiscol, Tamarit, and Ros 2000). The lifespan of ROS in the cytoplasm 
may explain why they don’t cause much damage when induced in the cytoplasm. 
However, their ability to produce aldehydes via lipid peroxidation could explain why 
there is a need for processes to prevent them from reacting with the cell membrane or 
organelle membranes. In contrast to ROS, the aldehydes can induce a significant amount 
of cluster damage, SSBs, and DSBs (Cabiscol, Tamarit, and Ros 2000). The most 
intensively researched aldehydes such as melonaldehyde and 4-hydroxyalkenals will 
produce SSBs and DSBs in the DNA backbone, adducts of base and sugar groups, cross-
linkage to other molecules, and lesions that block replication (Cabiscol, Tamarit, and 
Ros 2000).  
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These lesions that block replication are what I believe are truly important in controlling 
tumors, as they result in replicative senescence. Senescent cells are characterized by the 
irreversible proliferative arrest accompanied by characteristic changes in gene 
expression, metabolism, and cell morphology. Recently, aldehydes have been proposed 
to play the key role in the induction of radiation-induced senescence as aldehyde-
scavenging compounds can prevent senescence induction (Flor, Doshi, and Kron 2016). 
Interestingly, almost every CSC and CTC that has been isolated and analyzed has also 
been shown to have up-regulated expressions of aldehyde dehydrogenases (Chen, Chen, 
et al. 2009; Charafe-Jauffret et al. 2010; Ucar et al. 2009; Marcato, Dean, Pan, et al. 
2011; Marcato, Dean, Giacomantonio, et al. 2011). The daughter cells of these CSCs 
will either die or survive based on their continued expression of these enzymes.  
 
1.1.13.       Summary  
An outline of effects after radiation exposure and the role of cell fusion and ROS is 
presented in figure 1. First radiation, as previously mentioned radiation first deposits 
energy creating excitations and Ionizations causing direct effects such as DNA damage 
or indirect effects such as free radical production. Those free radicals can then further 
interact with DNA or interact with lipids in lipid peroxidation to cause aldehydes which 
can further interact with the DNA to cause ssb, dsbs, and cluster damage. Aldehydes can 
also interfere with methylation processes and effect genetic expressions leading to 
cancer as well. Depending on the degree of DNA damage their can be cell repair. 
Sometimes cell fusion is the repair process but cell fusion can be unstable and result in 
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the transfer of pluripotency markers and genetic mutations that lead to cancer. 
Otherwise, DNA damage and genetic mutations can lead to cell death in the form of 
apoptosis or necrosis. 
 
 
Figure 1. Summary of radiation, oxidative stress, cell fusion, and cancer. Adapted with 
permission (Clanton et al. 2015). 
 
Based on all of the previously identified cancer etiologies it can be seen that 
inflammation, mitochondrial dysfunction, radiation, cancer stem cells, cell fusion, and 
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even immune responses are all potential contributors to oncogenesis. They are also not 
mutually exclusive to each other. Due to the overlap of all of these paradigms it is 
suggested that if genetic damage and mutations are the matches that light the fire in 
cancer development, then inflammation may be the fuel that feeds the flame. From this 
information, we decided that targeting mitochondrial dysfunction would be a good 
pursuit. 
 
        Paradigm of Radiation Therapy 
The fact that radiation can cause the production of ROS and direct DNA damage makes 
it a dual edge sword, capable of both causing and treating cancer. Therefore, the intent of 
radiation therapy is to use ionizing radiation to kill cancer cells by damaging their DNA 
and inducing cell death or senescence, thereby stopping these cells from continuing to 
grow and divide. However, the selective bio-delivery of cytotoxic agents to target cancer 
cells with minimal adverse effects on healthy tissues remains a challenge when 
developing therapeutics (Emami et al. 1991; Stone et al. 2003). The most practical 
method of exposing cancer patients to radiation is through external-beam radiotherapy. 
With this approach, only a limited region of the body is irradiated with multiple beams 
of high-energy x-rays, which concentrate the absorbed dose to the tumor tissue and 
minimize the dose to normal surrounding tissues.  On the other hand, molecular 
radiotherapy (MR) uses a molecular structure, such as a monoclonal antibody, that 
attaches to antigens or receptors located only on the surface of tumor cells or 
extracellular components unique to tumor tissue. This molecule is labeled with a 
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radionuclide to deliver a cytotoxic level of radiation to disseminated disease sites 
scattered around the body. Unlike tumor-directed drugs and toxins, which kill only the 
targeted cells that the compounds enter, an exclusive feature of radionuclides is that their 
radiative emissions (Auger electrons, beta and alpha particles) can exert a “crossfire” 
effect, potentially destroying adjacent tumor cells even if they do not over-express the 
specific tumor-associated antigen or receptor.  Furthermore, molecular radiotherapeutics 
have the potential to eliminate both the primary tumor site and tumor cells that have 
spread throughout the body (metastases), including malignant cell populations that are 
undetectable by radiographic imaging, commonly referred to as minimal residual disease 
provided some means of making them specific and selective is found.   
 
Molecular radiotherapy has been used with increasing frequency as new targeting 
modalities are created. Generally, the radiotherapeutic agent has two components: a 
radionuclide and a carrier that specifically targets to tumor tissue. Examples of 
molecular carriers are peptides, which seek and attach to their corresponding cell-surface 
receptors, and monoclonal antibodies, which attach to antigens that are also expressed on 
the surface of tumor cells.  A radionuclide can be selected for its specific radiological 
characteristics, such as decay scheme, physical half-life, type of emitted radiation (e.g., 
alpha, beta particle and gamma emitter), and radiation range in tissue. It is this 
modularity, where the components can be varied like interlocking building blocks, which 
allows us to match the spatiotemporal pathophysiology specific to a tumor.   
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Clinically, the radionuclide 131I (NaI) has been used for decades for the treatment of 
papillary differentiated thyroid carcinoma and for the treatment of progressive medullary 
thyroid carcinoma using pre-targeting strategies with anti-carcinoembryonic monoclonal 
antibodies followed by 131I-labeled haptens (Salaun et al. 2012; Wong et al. 2000). For 
the case of Non-Hodgkin’s lymphoma, 131I-labeled anti-CD20 tositumomab monoclonal 
antibody (mAb) and 90Y-labeled rituximab mAb have been used with great success 
extending the progression-free and overall median survival of patients (Martinez et al. 
2017; Olney et al. 2014). Recently, the alpha-particle emitting 223RaCl2 (Xofygo®) has 
been approved by the FDA for the treatment of metastatic castration-resistance prostate 
cancer showing positive results by increasing the progression-free survival of patients 
(Nilsson 2016; Pandit-Taskar, Larson, and Carrasquillo 2014). In all the above 
strategies, the combination of lethal or sub-lethal doses of radiation and the 
immunotherapeutic effects of the monoclonal antibody has resulted in positive clinical 
results.  
 
The effectiveness of molecular radiotherapy depends on multiple factors, such as 
molecular parameters and pathophysiological barriers, including stability of the 
radiolabeled compound in serum and the unlabeled mAbs (IgG isotypes and fragments), 
plasma half-life, organ distribution or absorption, distribution, metabolism, and 
elimination (ADME), tumor affinity, penetration, uptake and internalization (Jain 1999; 
Ackerman, Pawlowski, and Wittrup 2008; Akabani, Kennel, and Zalutsky 2003). These 
limitations in molecular radiotherapy are exemplified in the literature (Ackerman, 
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Pawlowski, and Wittrup 2008) (Akabani, Kennel, and Zalutsky 2003). Figure 2 shows 
the limited penetration of an intact mAb using in vitro tumor spheroids, which elucidate 
the high interstitial tumor pressure encountered even in small tumor foci (Ackerman, 
Pawlowski, and Wittrup 2008). The in vivo limited distribution in tumor tissue of 125I-
labeled 210B mAb in a model of epithelial-to-mesenchymal transition (EMT)-tumor 
bearing mice of metastatic lung cancer has also been shown (Akabani, Kennel, and 
Zalutsky 2003). These examples demonstrate that molecular radiotherapy has significant 
limitations in the treatment of large solid tumors that need to be further addressed (Jain 
1999). Most strategies are based on a binary system where a radionuclide is attached to a 
compound, with a very low labeling efficiency, typically between 2 and 5%. 
Radionuclide-compound dissociation via radiolysis continues to be a significant problem 
that needs to be addressed (Chong et al. 2008; Milenic, Brady, and Brechbiel 2004).  
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Figure 2. In vitro studies using tumor spheroids showing that internalization of antigen 
reaches a steady state with diffusion, which limits penetration and thus therapy 
effectiveness. Depending on antigen concentration, antigen plateaus at different depths 
within the spheroid. Reprinted with permission (Ackerman, Pawlowski, and Wittrup 
2008). 
 
 
The prospect of using molecular radiotherapy for the treatment of minimal residual and 
micro-metastatic disease however has gained significant attention within the paradigm of 
cancer stem cells (Mehlen and Puisieux 2006). As previously mentioned, there lies a 
sub-population of tumor cells with stem cell-like properties and significant ability for 
self-renewal (Lin et al. 2016). The niche, as it is commonly referred to in the open 
literature, is a cluster of tumor cells where cancer stem cells reside, and it can produce 
florid microvascular proliferation and fulminant progression.  Even though the 
metastatic process is highly ineffective, it is estimated that about 90% of all cancer 
deaths are due to metastases (Mehlen and Puisieux 2006).  Many research groups, 
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including ours, are tackling this paradigm by using high-linear energy transfer (LET) 
particle emitting radionuclides, such as I-125, Au-198, Ra-223, At-211, and Ac-225, 
with the help of nuclear nanotechnologies (Ceder and Elgqvist 2016; Alessio et al. 2017; 
Akabani et al. 2002).  
 
This is because certain studies have elucidated that external beam radiotherapy has the 
potential to enhance angiogenesis, proliferation and thus speed up the process of 
metastases (Sofia Vala et al. 2010; Madani, De Neve, and Mareel 2008; Agemy et al. 
2008; Lee et al. 2017). Recent studies have shown how radiation impacts the different 
compartments of the tumor microenvironment (Leroi et al. 2016). Our group, in 
collaboration with others, used mutant mouse embryonic stem cells (mESC) as 
surrogates of cancer stem cells, where we carried out a study to elucidate the effects of 
radiation dose fraction by screening genes involved in proliferation and invasiveness. 
Our findings indicated that a total of 13 genes were involved, seven of them previously 
implicated and six new genes that had not been implicated prior to our study (Loesch et 
al. 2015). Our results indicated a dose-dependent gene over-expression at 2 Gy per 
fraction or lower (hyper-fractionation) followed by a steady decline afterwards up to 
14.5 Gy per fraction (hypo-fractionation, see Fig. 3). Destrin (Dstn) is an essential actin 
regulatory protein belonging to the actin-depolymerizing factor (ADF)/cofilin family, 
which are believed to control the actin-based cell motility (Carlier et al. 1997). A major 
property of ADF is its ability to enhance the in-vitro turnover rate called treadmilling of 
actin filaments to a value comparable to that seen in-vivo in motile lamellipodia, which 
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is due to ADF’s ability to use ATP hydrolysis in actin assembly to enhance filament 
dynamics (Carlier et al. 1997). Dstn appears to be a direct contributor to stem cell-like 
and Listeria monocytogenes-like motility (Bamburg, McGough, and Ono 1999; Carlier 
et al. 1997). This small actin-binding protein is also considered to be one of the key 
regulators of actin remodeling of the cytoskeleton, which is a crucial part of cytokinesis, 
cell migration, and polarized cell growth along with cancer cell migration and invasion 
(Klose et al. 2012). They have been linked to poor prognosis in cancer patients (Klose et 
al. 2012; Estornes et al. 2007; Wang et al. 2004; Wang, Eddy, and Condeelis 2007).  IQ-
domain GTPase-activating protein-1 (Iqgap1) has been shown to have significant 
expression upon the invasive front of tumors (Dong et al. 2006; Miyamoto et al. 2000; 
Nabeshima et al. 2002). It binds type 2 fibroblast growth factor (FGF2) to the cognate 
receptor called Fibroblast growth factor receptor 1, on the actin filaments which provides 
the force for the previously mentioned lamellipodial protrusion (Benseñor et al. 2007). 
Versican (Vcan) is a proteoglycan with diverse roles in role in cell adhesion, 
proliferation, migration, and angiogenesis which are all components of invasion and 
metastasis (Rahmani et al. 2006). Has anti-adhesive properties (Sakko et al. 2003). 
Elevated levels of Vcan have been reported in most malignancies to date (Karamanos et 
al. 2012). Dynein Light Chain Roadblock-Type 1 (Dynlrb1 or Km23-1) is known as a 
motor protein that transports cargo within the cell but Km23-1 is also involved in the 
movement or migration of cells. Plays important role in TGF-beta signal transduction, 
most specifically Ras activation (Jin, Ding, and Mulder 2012). Knockdown has been 
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shown to decrease RhoA activation and inhibit human colon carcinoma cell invasion in 
wound healing assays (Jin et al. 2012). 
 
  
Figure 3. Beta-gal expression of invasion-related genes after various single radiation 
doses showing an enhancement at doses below 2 Gy and subsequent reduction 
afterwards.  The genes involved were Dstn, Iqgap1, Vcan, and Dynlrb1. These four 
genes are involved in cell proliferation, angiogenesis, invasion and migration adapted 
from data obtained in previous study (Loesch et al. 2015).   
 
The significance of this study indicates that radiation dose (dose per fraction) is 
potentially a powerful contributor to angiogenesis, proliferation and thus metastases, 
which is corroborated by multiple recent studies (Gu et al. 2015; Li et al. 2013; Grabham 
and Sharma 2013). Therefore, it has a significant impact in tumor control probability 
(TCP). Molecular radiotherapy, on the other hand, delivers radiation to target tissues 
stochastically at a low effective dose rate but very highly localized absorbed dose; 
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therefore, it is postulated that molecular radiotherapy would be more effective in treating 
minimal residual disease, small tumor foci and metastases, without enhancing the genes 
found to be involved in angiogenesis, proliferation and invasiveness. This is especially 
true if the radiation is high-LET, which has been shown to reduce metastasis and 
angiogenesis in contrast to x-rays (Bruland et al. 2008; Grabham and Sharma 2013). 
This is probably again related to the ability of high-LET radiation to produce 
significantly more aldehydes and thus senescence of the cancer cells (Zhang et al. 2016). 
Using senescence-associated β-galactosidase (SA-β-Gal) as a marker of senescence, data 
has shown that it takes 10 Gy X-rays (LET 4 kev/μm), 5 Gy Carbon (LET 80 kev/μm), 
and only 3 Gy for 56Fe to begin to plateau in their ability to cause a percentage of 92-1 
cells to express SA-β-Gal (Zhang et al. 2016). 56Fe also plateaued around 100% of the 
cells while X-rays and carbons only plateaued around 60% of the cells showing 
expression (Zhang et al. 2016). 
 
Our laboratory has produced radioactive nanoparticles using 211At, 125I and 198Au 
functionalized with multiple agents, including cell-penetrating peptides, showed the 
cytotoxic capacity of these probes against cancer cells. Two of these, 211At and 125I, are 
high-LET radiation meaning they may be capable of reducing invasion and inducing 
senescence more effectively then X-rays as discussed previously. These nanoparticles 
will be the ones used in this dissertation research. We studied the microdosimetry 
characteristics of the nanoparticles (Hamoui 2015; Pulley 2015). The major benefit of 
having multiple radioactive atoms per nanoparticle is based on the capacity to deliver 
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multiple “hits” of highly focused energy deposition to a single cell structure, such as the 
cell nucleus or mitochondria of the same cell, thus increasing the probability of cell 
death. Therefore, nuclear nanotechnologies are considered a promising strategy in 
molecular radiotherapy.  
 
        Enhanced Permeability and Retention  
Gold nanoparticles (AuNPs) offer unique opportunities in the delivery of biologically 
relevant compounds (e.g., radionuclides) due to the enhanced permeability and retention 
(EPR) in neoplasms (Ghosh et al. 2008; Peer et al. 2007). Yet, the mechanism of EPR, 
beyond the enhanced permeability of the tumor vasculature aiding the effect, hasn’t been 
fully explained in the current literature. Once the AuNPs are within the neoplasm, it is 
believed they can enter cells via macropinocytosis or some other form of specialized 
endocytosis, with or without involvement of surface receptors. I suggest that the 
enhanced retention of AuNPs in cancer cells may also be caused, in part, by the 
interaction of AuNPs with the mitochondria because of mitochondrial dysfunction 
induced changes in electrostatic potential (See Fig. 4). As previously mentioned from 
Warburg’s observations (Warburg 1924), the main evidence of mitochondrial 
dysfunction was the switch from aerobic to anaerobic respiration, which results in a 
significant increase in reactive oxygen species (ROS) in neoplastic cells (Wallace 
2005b). Mitochondrial dysfunction has also been characterized by increases in 
mitochondrial fission, resulting in either an excess of long chain or clustered 
mitochondrial fragments frequently seen in neoplastic cells (Zhao et al. 2013; Alirol and 
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Martinou 2006; Wallace 2005a). More recently, studies have also found that the vitiation 
of ATP synthesis due to mitochondrial uncoupling in response to disruptions of the 
mitochondria’s membrane potential, can promote the Warburg effect, potentially 
contributing to the chemoresistance of leukemia cells (Samudio, Fiegl, and Andreeff 
2009). Therefore, to elaborate further we suggest that mitochondrial dysfunction leads to 
differences in mitochondrial membrane and/or surface potentials, which potentially 
enhance the EPR effect via electrostatic attraction. 
 
 
Figure 4. Gold nanoparticles (AuNPs) offer unique opportunities as carriers in the 
delivery of theranostically relevant compounds to the tumor via the enhanced 
permeability and retention effect (EPR). 
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To give credence to membrane and surface potentials enhancing the EPR effect, various 
studies have shown considerable internalization of AuNPs by cancer cells followed by 
their interaction with the mitochondria (internalization or adherence to membrane); in 
some instances, this mechanism was even used to try and induce apoptosis or radio-
sensitization of cancer cells (Mkandawire et al. 2015; Taggart et al. 2014; Yang et al. 
2015). Other studies validated this assessment by showing that the mitochondrial surface 
potential has considerable influence on the uptake and even the potential cytotoxicity of 
gold nanoparticles (Zhao et al. 2012; Frohlich 2012). Varying the surface charges of the 
nanoparticles could therefore be the key to targeting the cancer stem cell sub-
populations. For example, Liu et al. demonstrated the size and surface charge effects of 
gold nanoparticles on interactions with phagocytic and nonphagocytic cells, RAW 264.7 
and HepG2 cells, respectively (Liu et al. 2013). Due to the phagocytic nature of cancer 
stem cells, the use of negatively charged nanoparticles may promote a cancer stem cell’s 
uptake of nanoparticles preferentially over the non-phagocytic cells of healthy tissue. 
This is also seen with the metastatic and highly-invasive B16F10 melanoma populations, 
which take up nanoparticles readily and distributes them into their golgi apparatus and 
endoplasmic reticulum (Chang et al. 2008).  
 
        PEGylation for Stabilization, Labeling, and Targeting 
Bare gold nanoparticles are unsuitable for in vitro and in vivo use, as they aggregate in 
the biological environment, resulting in negligible circulation and uptake by the tumor 
(Ting et al. 2010). We have found (unpublished results) that citrate-encapsulated gold 
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nanoparticles are unsuitable to nebulize due to aggregation. It is therefore necessary to 
provide a surface protectant to limit aggregation, as well as to provide targeting or 
aerosolizing properties. One method is to provide a biologically inert coating of 
polyethylene glycol (PEG) in a so-called “corona” (Ishii et al. 2004). In this case, 2-5 
kDa PEG chains, labeled with a thiol group on one end, are put in solution with the gold 
nanoparticles at a ratio of 1000:1. The sulfur in the thiol compound covalently bonds to 
the gold nanoparticle surface, leaving the inert PEG corona to protect the nanoparticle, in 
a process known as PEGylation. In practice, variations in these PEG chains are included 
to tailor the chemical properties of the nanoparticles.  Here, 2 kDa methoxy-PEG-thiol 
(CH3O-(CH2CH2O)n-CH2CH2SH), with the chemically inert methoxy group, is mixed in 
a ratio of 98:2 with 5 kDa carboxymethyl-PEG-thiol  (CH2COOH-(CH2CH2O)n-
CH2CH2SH). The carboxymethyl-PEG-thiol is roughly twice as long, leaving the 
carboxymethyl- group exposed on the PEGylated nanoparticle surface. The 
carboxymethyl- group is activated for conjugation to targeting ligands (de Mol and 
Fischer 2010). In a common technique, repeated here, N-hydroxysuccinimide (NHS) is 
used with (N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride) (EDC) and 
several buffers to link proteins, such as monoclonal antibodies, to other molecules (Reist 
et al. 1999; Lewis et al. 2001; de Mol and Fischer 2010; Bartczak and Kanaras 2011).  
 
PEG, which is also one of the main coating agents used during gold nanoparticle 
synthesis, has been shown to induce mitochondrial fusion by reducing the 
mitochondria’s membrane potential (Wojcieszyn 1983; Robinson et al. 1979). The 
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importance of fusing mitochondrial fragments in cancer progression is emphasized by 
studies showing that the induced fusion of fragmented mitochondria results in cell cycle 
arrest in lung cancer (Rehman et al. 2012). PEG-AuNPs reduce the surface potential of 
the fragmented mitochondria, causing fusion around the AuNPs; therefore, PEG 
properties may also be some of the key reasons why PEG-AuNPs have enhanced 
retention in neoplastic cells. This enhanced retention is corroborated by a study where 
PEG-AuNPs were shown to be able to reduce the surface potential of fragmented 
mitochondria, induce fusion, arrest cell cycle, and then induce apoptosis in chronic 
myeloid leukemia cells (Huang et al. 2014). Reducing the surface potentials of the 
fragmented mitochondria would potentially result in either a situation where the 
mitochondria regains its metabolic activity or depletes its capacity of supplying ATP at 
the quantities required by the neoplasm, which would explain PEG’s dramatic ability to 
induce apoptosis in some colon cancer cell lines (Roy et al. 2001).  
 
        The Radiochemical/biological Properties of 198Au 
The radiological properties of 198Au grains covered in platinum made this radioisotope 
popular on permanent implants for head and neck cancers, replacing the previously 
employed radon seeds (Hoskin and Coyle 2011). 198Au is a beta emitter produced from 
the neutron activation of stable 197Au. It has a half-life of approximately 2.7 days and 
decays to an isotope of mercury (Hoskin and Coyle 2011). Production of 198Au can 
effectively be carried out utilizing a nuclear reactor and performing (n, γ) activation due 
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to the reasonable thermal neutron cross section of 197Au (σ=98.65 b) (Goswami et al. 
2016). 
 
The radionuclide emits a 0.412 MeV gamma photon and a βmax of approximately 0.96 
MeV. β particles are low LET radiation and generally can only travel a few micrometers 
to centimeters in soft tissues, which makes 198Au great for targeting the tumor and 
reducing damage to normal, healthy tissues surrounding the tumor. The gamma radiation 
emitted by 198Au can also be used for SPECT (not optimal due to necessary collimation 
of high energy gammas) or Cerenkov imaging (Black et al. 2014). 
 
        The Radiochemical/biological Properties of 125I 
The radiological properties of 125I have facilitated its extensive use in brachytherapy for 
the treatment of skin, prostate, lung, and brain tumors, while also being used in certain 
situations for thyroid imaging (anatomic and physiologic function) and as a label in 
radioimmunoassays (Al Mahmoud et al. 2008; Garretson, Robertson, and Earle 1987; 
Gutin et al. 1984; Chen et al. 1999; Beydoun, Bucci, and Malouf 2014; Prince, Zu'bi, 
and Haag 1979; Corrie, Ratcliffe, and Macpherson 1981; Goddard et al. 1986; Harper et 
al. 1961). It has also been used with moderate success in the treatment of multiple 
recurrent solid tumors (Gaspar et al. 1999; Ling 1992).  
 
The half-life of 125I is 60.14 days and decays by electron capture (EC) to the excited state 
of 125Te, which immediately emits a 35.5 keV gamma ray (Friedlander and Orr 1951). 
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This is followed by the emission of short-range, highly localized, low-energy conversion 
and Auger electrons. Conversion electrons are ejected with a maximum energy of 35 
keV while the 21 typical Auger electrons produced per decay possess energies ranging 
from 0.07 to 30.1 keV (Silberstein 2012). Auger-electron emissions have also been 
found very effective for therapy and diagnostics (Stepanek, Larsson, and Weinreich 
1996; Wieland et al. 1981).  
 
The Auger effect is the primary process by which 125I decays and produces cellular 
damage (Kassis 2004; Hofer et al. 1992; Hofer 1996). When 125I decays it produces an 
energy deposition of approximately 106 cGy, in a 2-nm radius spherical volume 
surrounding the point of decay (Humm, Howell, and Rao 1995; Balagurumoorthy et al. 
2012). Based on the energies of the electrons produced by 125I, the electrons will 
approximately travel 100 nm in water and only 10 nm in gold (Vaughan 1986; Piotr et 
al. 2013). This range will limit the effective diameters of the AuNPs to 20 nm so that 
radiative emissions from 125I, potentially at the core of the AuNPs, will be able to reach 
outside the AuNP (Dulkeith et al. 2004; Hangleiter and Hacker 1990; Zhang and Yates 
Jr 2010).  
 
While Auger electrons possess relatively low-energies, their cytotoxic potential parallels 
that of high-LET radiation (e.g. alpha particles) when their decay occurs near DNA 
molecules (Bradley, Chan, and Adelstein 1975; Hofer 2000; Hofer and Hughes 1971). 
As a result, the electron decay of 125I produces DNA double strand breaks and cluster 
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damage, detectable up to 70 angstroms from the decay site, making it a very potent 
therapeutic if near the nucleus or organelles (Martin and Haseltine 1981; 
Balagurumoorthy et al. 2012). Moreover, the Auger electron cascade in gold serves as a 
key benefit to the synthesis of 125I-AuNPs, as the effect potentially enhances the 
radionuclide’s cytotoxicity (Rahman et al. 2009). Auger cascades and the highly 
localized deposition of energy around the AuNPs are key features of how AuNPs 
influence the mitochondria and radiosensitization (Taggart et al. 2014). The potential for 
these 125I-AuNPs to attach to lipid membranes is also a key component as the ROS 
produced by the Auger electrons may induce lipid peroxidation and aldehyde 
production, inducing senescence, which seems to be potentially corroborated by a recent 
study showing that the interactions of Auger electrons on the cell membranes could be 
cytotoxic (Paillas et al. 2016). 
 
        The Radiochemical/biological Properties of 211At 
Out of the many alpha emitters known only a handful of them are suitable for use in 
targeted, clinical therapies (211At, 212Bi, 213Bi, 223Ra, 225Ac, and 227Th) (Guerard, Gestin, 
and Brechbiel 2013). Alpha-emitters are therapeutically suitable for sites of minimal 
residual disease (MRD), or tiny clusters and micrometastases, because like auger 
electrons alpha particle are high-LET and travel very short ranges (Imam 2001b). The 
radionuclide, 211At, is considered an ideal candidate for alpha-emitter TRT strategies due 
to its relatively short half-life (7.214 h) and desirable decay chain (Zalutsky et al. 1989). 
Astatine-211 decays by electron capture to 211Po (branching ratio = 0.582), which in turn 
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decays by alpha-particle emission. Following electron capture 211At can alternatively 
decay by alpha-particle emission to 207Bi. While 211Po is available in the metastable state 
as 211mPo from other production methods, it is not fed by 211At decay due to high nuclear 
spin and associated low decay probability (Groppi et al. 2005). The alpha emitted from 
the decay of 211At can travel a mean path length in tissue of approximately 55-80 µm 
(Imam 2001a). During decay, several x-rays in the 77-92 keV range are emitted 
additionally. Like I125 this would potentially allow in vivo imaging and estimation of 
internal dose distributions utilizing SPECT (Zalutsky and Pruszynski 2011; Turkington 
et al. 1993). 
  
Compared to the other alpha-emitters, 211At has the most clinically useful half-life since 
half-lives any shorter than a few hours prove difficult to manufacture, transport, and 
administer without significant decay. Unlike routinely produced radionuclides with short 
half-lives used in positron emission tomography (18F), the processing and labeling 
procedures for therapeutic drugs have not been automated to the same degree. Half-lives 
longer than a day or two introduce issues with specific activity, labeling efficiency, and 
committed doses. At first, the significant energy yield of alpha-particles associated with 
the heavier radionuclides would seem beneficial. However, due to the multiple decays 
involved, it is likely that daughters will have dissociated from the targeting molecule and 
transported away from the tumor site, such that further emissions are ineffective (Palm et 
al. 2004; Guerard, Gestin, and Brechbiel 2013). This is especially true when targeting 
micro-metastases and cell clusters (Aurlien et al. 2000).  
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The biological effects of 211At alpha-emissions are fundamental to its clinical efficacy. 
Alpha-particles like the Auger electrons produced from 125I are high-LET radiation. 
Alpha-particles are often produced with kinetic energies 5-20 times the kinetic energies 
of beta particles (like those emitted by 198Au). While both high-LET and low-LET 
radiation deposit energy via electronic interactions, the high-LET radiation will deposit a 
high density of ionizations surrounding the track or path it takes through a medium. The 
number of ionizations and distance between ionizations along a particles path plays an 
integral part in the amount of energy transferred per unit path length. As such the 
probability of creating substantial damage is substantially higher and results in more cell 
death per unit dose delivered. Alpha-particles have a higher LET by 2-3 orders of 
magnitude, resulting in much higher cytotoxicity and relative biological effectiveness 
(See Fig. 5) (Chen et al. 2012, Hauck et al. 1998). The higher density of ionizations 
results in a higher concentration of double-strand breaks and other densely manifested 
lesions produced by alpha-particles traversing the cell nucleus. The result is an a 
significantly reduced cellular repair ability (Raju et al. 1991, Dadachova 2010, Chen et 
al. 2012). 
 
  45 
 
Figure 5. A relative comparison of radiobiological characteristics of various radiations 
as a function of absorbed dose, showing the relatively superior effectiveness of high-
LET radiation, such as alpha-particles and auger electrons. X-rays and beta particles 
would be on the low-LET curve. 
 
As previously mentioned, high-LET has been shown to reduce metastasis and 
angiogenesis in contrast to x-rays (Bruland et al. 2008; Grabham and Sharma 2013). 
This is potentially again related to the ability of high-LET radiation to produce 
significantly more aldehydes and thus the senescence of cancer cells but other pathways 
still need to be investigated (Zhang et al. 2016). Using SA-β-Gal as a marker of 
senescence, data has shown that it takes 10 Gy X-rays (LET 4 kev/μm), 5 Gy Carbon 
(LET 80 kev/μm), and only 3 Gy for 56Fe to begin to plateau in their ability to cause a 
percentage of 92-1 cells to express SA-β-Gal (Zhang et al. 2016). The effect of 56Fe also 
plateaued with induced senescence around 100% of the cells while X-rays and carbons 
only plateaued around 60% of the cells going into senescence (expressing SA-β-Gal) 
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(Zhang et al. 2016). However, this is by external beams and potentially cannot be used to 
describe high-LET radiation from nanoparticles on the cell membranes or mitochondria 
of cancer cells, especially those that are phagocytic. Furthermore, the average number of 
particle traversals to result in a certain survival fraction is very dependent upon the 
distribution of the emission source, the concentration of the source within the cell, and 
the cell cycle phase (Sgouros 2008). 
 
        Combining AuNPs with Radionuclides 
Besides 198Au, a major impediment to the use of 125I or 211At in their free states, like all 
other isotopes of iodine or astatine, is that it has very little affinity for tissue other than 
the thyroid, even in the presence of a tumor (Lundh et al. 2006). Therefore, seeds and 
various other carriers are utilized to mitigate this issue and allow for targeting specific 
areas of interest. Utilizing AuNPs would potentially increase the efficacy of these 
radionuclides not only as a therapeutic agent in tumors of the thyroid, but for other 
primary and secondary neoplasms all over the body. Gold is preferred construct in the 
production of nanoparticles for biomedical applications as it is toxicologically inert and 
relatively easy to functionalize (Khan 2011). This is a property that other therapies such 
as seed brachytherapy does not have the ability to perform; it may target specific tumors 
after surgical intervention but since it does not circulate in the blood there is no means of 
targeting CTCs or sites of metastasis besides potential immune responses (i.e., bystander 
effects).  
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We hypothesized that radionuclide integrated AuNPs could potentially harness the 
targeting and delivery potential of AuNPs with the therapeutic potential of radionuclides. 
The potential of utilizing PEGylated radionuclide-AuNPs is supported by the 
observation of the cellular ultrastructure obtained from transmission electron microscopy 
(TEM) images that reveal the internalization of AuNPs, which were distributed 
throughout cytoplasmic vacuoles and damaged mitochondria, which subsequently 
accumulated in areas surrounding the nuclear membrane (Huang et al. 2014). Wang et 
al. observed the accumulation of gold nanorods in the mitochondria of tumor cells while 
normal cells with normal mitochondria were spared (Wang, Liu, et al. 2011). In addition, 
Hainfeld et al. observed a 19:1 in-vivo accumulation of intravenously injected AuNPs in 
glioma-tumor bearing mice versus normal brain tissue (Hainfeld et al. 2013).  AuNPs are 
now also being routinely used to target the mitochondria (Wang, Liu, et al. 2011; Kirkby 
and Ghasroddashti 2015; Karatas et al. 2009), and if concentrations are high enough can 
provide favorable characteristics as a contrast agent in CT imaging at least for one time 
use (Hainfeld et al. 2006). Further studies would need to be performed to investigate 
complications with repeated administration. As an example, the combination of 125I with 
AuNPs would give us the potential to increase targeting of subcellular components with 
Auger electrons, a key component of 125I radiotoxicity (Narra et al. 1992). This includes 
targeting the nuclear DNA of the cell and even the mitochondrial DNA, increasing the 
treatment efficacy. Even interactions with the lipids of the cellular membranes, causing 
aldehyde production via lipid peroxidation, may increase the incidence of radiation-
induced senescence (Flor, Doshi, and Kron 2016). This would be a benefit of using high-
  48 
LET radiation like the Auger electrons and alpha particles emitted from 125I and 211At, 
respectively. These are all items that seed brachytherapy does not have the potential to 
accomplish, seeing how 125I seeds are encased in titanium, which block the Auger 
electron emissions. 
 
      Synthesis of 125I/211At-AuNPs 
Even though the combination of these two modalities is intriguing, the synthesis of gold 
nanoparticles (AuNPs) containing halides (Iodide or Astatide) has been arduous. My 
research focused on 125I-AuNPs synthesis. Routinely, it has been found that the addition 
of iodine during nanoparticle synthesis results in the aggregation of gold nanoparticles, 
mainly due to a destabilization of the surface potentials of partially formed nanoparticles 
via displacement of the stabilizing citrate groups (Cheng, Dong, and Wang 2003; Daniel 
and Astruc 2004).  However, after synthesis, AuNPs have been coated with 125I, which 
was added simultaneously with PEGylating “capping” agents. Capping the iodine coated 
AuNPs with PEGylating agents was found to provide effective enhancement of x-ray/CT 
imaging while also increasing the biological half-life of the radionuclide in target tissues 
(Kim et al. 2012). 
 
Gold and iodine atoms have very interesting interactions, there is a process called 
chemisorption, referring to the way in which halide ions and organic compounds absorb 
onto the surfaces of transition-metals through mutual interactions (Pyykkö 2005). Within 
this dissertation, iodine was added during synthesis of AuNPs, at reflux, to generate 
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polyiodides or polyiodines, which are hypervalent and show exceptional electrical 
conductivity (potentially contributing to free radical production) integrated into the 
structure of the AuNP.  
 
Polyiodides are a fascinating concept in structural chemistry, with established structural 
characterizations ranging from 𝐼2
−to 𝐼29
3− (Svensson and Kloo 2003). Even though the 
anionic forms are the most established and researched, the relatively stable cationic 
forms (polyiodines) are possible as well (Merryman, Corbett, and Edwards 1975). To 
our synthesis, the cationic formation was the most relevant because they are already 
known to readily occur in metal chloride solutions in the presence of reducing agents 
(Merryman, Corbett, and Edwards 1975). The nature of polyiodide and polyiodine 
bonding is not explained by conventional covalent bonding models and have thus been 
the object of much experimental and theoretical speculation (Svensson and Kloo 2003). 
Neutral iodine and gold have n-1 valence electron configuration while each of their ionic 
forms have closed valence shells (Svensson and Kloo 2003).  
 
The most important correlation between the gold and iodine is that their 
electronegativities are almost identical, gold having a 2.4, while iodine has a 2.5 
(Svensson and Kloo 2003). As such, iodine has been demonstrated to exhibit metal-like 
behavior (Tang et al. 2014). Additionally, considerable evidence has shown gold to 
behave chemically like halogens (Greenwood and Earnshaw 1984; Svensson and Kloo 
2003). As a result, many gold-iodine complexes have almost identical bond angles along 
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with very similar bond lengths to those of polyiodides: (i.e., AuI4
- and I5
-) (Svensson and 
Kloo 2003). This also means that the I-I interactions in binary gold are most 
appropriately described as being analogous to those observed in polyiodides and 
polyiodines (Svensson and Kloo 2003). Because of this, it was found reasonable to 
hypothesize that polyiodides and polyiodines can be incorporated directly into the 
structure of gold nanoparticles.  If successful, this would lead to the synthesis of highly 
cytotoxic 125I-AuNPs, readily capable of being functionalized using PEG and tumor-
targeting biomolecules (e.g., cell-penetrating peptides) (Floren, Mager, and Langel 2011; 
Hallbrink et al. 2001; Zorko and Langel 2005). Therefore, below we describe our early 
experimental results in the synthesis of 125I integrated gold nanoparticles that are for now 
PEGylated, but due to stability during synthesis, can potentially be functionalized with 
any other coating agent of AuNPs. A similar procedure was performed for 211At as well. 
 
 Synthesis of Fluorescent AuNPs Probes 
The highly sensitive nature of fluorescent probes for assays and detection techniques 
makes them among the most popular biological option for many researchers. However, 
to combine fluorescent probes with AuNPs is a rather arduous task. This is because 
AuNPs show the highest quenching (decrease in fluorescence intensity) ability of any 
compound tested, up to 99% (Swierczewska, Lee, and Chen 2011). Even for AuNPs of 
approximately 1 nm radius there is significant fluorescence quenching of lissamine dye 
molecules, not only because of increases in the nonradiative decay rate but reductions in 
the dyes radiative decay rate as well (Dulkeith et al. 2002). Similar probes have shown 
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that decreases in the excited state lifetime and fluorescence quantum yield observed 
upon binding to AuNPs could be traced back to the previously mentioned decrease in 
nonradiative rate or in other word the increase in nonradiative deactivation rate 
(Cannone et al. 2006). However, the degree of quenching appears to be length dependent 
and as such fluorescent-PEG-thiol compounds may be advantageous. However, there is a 
caveat to using these nanoparticles with long-chain PEGs to image cancer cells, the 
longer the PEG chain the lower the uptake (Cruje and Chithrani 2014). Therefore, a 
combination of 2kDa methyl-PEG-thiol and 5kDa Cy5.5-PEG-thiol was used together to 
prevent the Cy5.5 from getting too close to the AuNPs surface to entirely quench the 
fluorescent signal. 
 
 Delivery of Theranostics to the Lungs 
A main advantage of utilizing these radionuclides (I-125, Au-198, and As-211) is that 
they are theranostics; capable of being used therapeutically and diagnostically (imaging). 
In vivo imaging is an important tool for preclinical studies with particular interest on 
lung function and disease. This is because lung cancer is the leading cause of cancer-
related deaths for both men and women throughout the developed world (Purandare and 
Rangarajan 2015). The widespread availability of multimodal animal imaging systems 
and the rapid improvement of diagnostic contrast agents available have allowed 
researchers to noninvasively study lung function and pulmonary disorders (van der 
Schee et al. 2015). There are several imaging modalities used in molecular imaging such 
as planar radiography, computerized tomography (CT), single photon emission 
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tomography (SPECT), positron emission tomography (PET/CT), magnetic resonance 
imaging (MRI), Cherenkov luminescence imaging (CLI), PET/MRI, and 
bioluminescence (Auletta et al. 2017; Kiessling et al. 2014; Martinez-Rodriguez and 
Banzo 2017). Each one of these imaging modalities has their own set of advantages and 
limitations. Using the above imaging modalities makes it possible to diagnose, track, and 
quantify biological processes over time. A combination of modalities also offers great 
insight into tumor progression and treatment efficacy. Bioluminescence, fluorescence, 
planar x-ray, CT, MRI, and nuclear imaging modalities (PET and SPECT) for the study 
of lung function and pulmonary disorders have been employed in the preclinical setting 
(Shaw, Kirsch, and Jacks 2005).  However, in humans the diagnosis and therapy of lung 
diseases continue to be problematic (Garrastazu Pereira et al. 2016; Hussain 2016; 
Anchordoquy et al. 2017; Landesman-Milo, Ramishetti, and Peer 2015; Shete et al. 
2014). Even with tremendous effort to treat, the overall 5-year survival for all stages of 
lung cancer are dismally low at only 15% because most patients often present at 
advanced stages when no curative treatment is still an option (Mountain 1997). The 
direct delivery of drugs to the lungs is a difficult task that requires the merging of 
engineering principles in aerosol sciences and molecular imaging, including the 
sustained drug release after inhalation (Iyer, Hsia, and Nguyen 2015; Muralidharan et al. 
2015; Mortensen and Hickey 2014; Loira-Pastoriza, Todoroff, and Vanbever 2014; 
Darquenne et al. 2016).  
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 The Merit of Nebulizers in Drug Delivery to the Lungs and Therapy 
The treatment of lung diseases has drastically improved alongside nebulizer 
development and research enabling the production of quasi-monodisperse aerosols 
capable of penetrating the deepest regions of the lung (Darquenne et al. 2016). However, 
due to inconsistent reporting and nebulizer variations many studies have been 
irreproducible. Therefore, the standardization of the these systems, including the devices 
and techniques or procedures could provide researchers the capacity to reproduce studies 
and one day duplicate the consistent delivery of aerosols to patients (Jacob, O'Driscoll, 
and Dennis 2003). Furthermore, the advent of active biological nanoparticles as drugs is 
spurring the research to characterize aerosol delivery, pharmacokinetics, 
pharmacodynamics, and overall safety (Mitchell, Suggett, and Nagel 2016; 
Dyawanapelly, Kumar, and Chourasia 2017). This includes not only radionuclide-
integrated metal nanoparticles but also chemotherapeutics modified into nanoparticles. 
These nanoparticle-based drug nebulization studies will require preclinical animal 
models to assess the safety and efficacy of these nanoparticles under FDA guidelines. 
The FDA maintains a product-focused, science-based regulatory policy and has 
regulated nanotechnology-based products under pre-existing statutory authorities (Food 
and Drug Administration 2014). The current framework for safety assessment could be 
considered sufficiently robust for this application and flexible enough to be appropriate 
for a variety of materials such as nanomaterials. As an example, CytImmune Sciences, 
Inc produced Aurimune (CYT-6091), a colloidal gold approved for Phase II Preclinical 
studies for solid tumors utilizing a TNF- targeting mechanism (Libutti et al. 2010; 
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Paciotti et al. 2004). The developed nebulization system could be used to help develop 
translational physiologically based pharmacokinetic models of radiolabeled, 
functionalized gold nanoparticle aerosols inhaled by animal models of disease. This will 
in turn help develop therapeutic strategies for those aerosols in humans.  
 
 The Vibrating Mesh Atomizer 
The nebulizer system developed in this dissertation consists of an annular piezoelectric 
element or crystal that surrounds/contacts a mesh. This mesh consists of thousands of 
tiny laser-drilled holes, each possessing a conical structure. To bias nebulization in one 
direction, the larger cross-section of these conical structures all face the fluidic drug 
reservoir. As the piezoelectric element activates, it vibrates the mesh at high frequencies 
(typically 1-3 MHz). This deforms the fluid supply and thus ejects a population of fluid 
particles on the opposite side of where the fluid reservoir was (Watts, McConville, and 
Williams 2008). This provides the name of these devices, vibrating mesh nebulizers, 
versus jet nebulizers. Mesh nebulizers have an almost silent operation, high output 
efficiency, and have minimal residual volume (most effective at delivering aerosol 
throughout lungs) (Ari 2014). Furthermore, mesh nebulizers can nebulize low drug 
volumes. The size of the pores or laser drilled holes, the reservoir, the aerosol chamber, 
and the output rate of mesh nebulizers, can be adjusted for different drugs to optimize 
aerosol drug delivery to patients. Although human studies with mesh nebulizers are 
limited, in vitro studies demonstrated approximately 2-3 times higher lung deposition 
with mesh nebulizers when compared to jet nebulizers (Farkhani et al. 2014; Lluis and 
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Cosma 2010; Ari and Fink 2012; Rau, Ari, and Restrepo 2004). It is important to note 
that aerosol output and the actual inhaled fraction will be largely influenced by drug 
formulations. This is because the performance of these vibrating mesh nebulizers could 
be hindered by suspensions with a high surface tension or those that could crystalize 
upon drying as reports exist regarding the blockage of the mesh perforations (Dhand 
2002; Ari 2014). This was particularly true for our studies as we found citrate 
encapsulated gold nanoparticles accumulated or aggregated in the nebulizer while 
PEGylated gold nanoparticles did not. In fact, the larger the ratio of PEG to AuNPs 
utilized for the experiment the faster the nanoparticles were aerosolized thus it was 
significantly reducing the surface tension of the nanoparticles. 
 
 Aerosol Characterization 
Several characterization techniques and attributes exist for a thorough depiction of an 
aerosol and its predicted behavior. One of the key characteristics is the aerodynamic 
diameter. It is defined as the equivalent diameter of a unit density having the same 
settling velocity due to gravity as the particle under scrutiny or interest of whatever 
shape and density. It is advantageous to formulate these attributes so that one can 
account for the particle aspect ratio, potentially shape, and size of an individual particle. 
Since aerosols are the sum combination of a large population of particles, the population 
can be described in multiple ways such as number median aerodynamic diameter 
(NMAD), volume median aerodynamic diameter (VMAD), mass median aerodynamic 
diameter (MMAD), and surface median aerodynamic diameter (SMAD). These values 
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are also often provided with a geometric standard deviation, which will allow you to 
correlate between each one of them using the Hatch and Choate Relation.  
 
 Comparison of Human and Mouse Lungs 
The route of entry for internalization of airborne nanoparticles is most significantly 
inhalation  (Yang, Peters, and Williams 2008). In mammals, the respiratory system is 
typically partitioned as the extra thoracic/nasopharyngeal region (nose, mouth, pharynx, 
larynx), tracheobronchial region (trachea to terminal bronchioles: main bronchus, lobar 
bronchus, segmental bronchus, sub-segmental bronchus, conducting bronchiole), and the 
pulmonary/alveolar region (respiratory bronchiole, alveolar duct, alveolar sac, alveolus). 
Several trends can be observed as you go deeper into the lungs such as an increase in 
branching, the total cross-sectional area, and the residence time in the airway. In other 
words, the relationship exists that as the length/diameter decreases and branching 
number increases, there is a reduction in velocity and thus an increase in residence time. 
These trends can be used to distinctly characterize each airway in the lungs, thus aerosol 
particle deposition and subsequent deposition mechanisms should be considered distinct 
per location in the lung.  
 
There are many important considerations regarding the differences between human and 
murine lungs  (Mendez, Gookin, and Phalen 2010; Irvin and Bates 2003; Bennett and 
Tenney 1982). For one thing, mice are obligate nose breathers and as such the 
contribution of the upper airways must be taken into consideration with un restrained 
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mice when doing measurements of respiratory function. Mice have a total lung capacity 
(TLC) of approximately 1 ml while humans are roughly around 6,000 ml (Irvin and 
Bates 2003). Both humans and mice have 5 lobes distributed between both lungs 
however the left lung in mice is composed of a single lobe (see Fig 6). 18% of the mouse 
lungs is occupied by parenchyma while only 12% of the human lungs is occupied by 
parenchyma (Irvin and Bates 2003). The mouse lung alveoli are significantly smaller as 
well with a mean linear intercept of 80 μm compared to that of 210 μm in humans (Irvin 
and Bates 2003). The blood-gas barrier thickness, which would potentially have 
important implications in nanoparticle translocation, gas exchange, and parenchymal 
lung mechanics, is 0.32 μm in mice and 0.62 μm in humans (Irvin and Bates 2003). The 
number of respiratory bronchioles and airway generations are significantly fewer as well 
with only 13–17 compared to the more numerous 17–21 generations observed in a 
human lung (Irvin and Bates 2003). 
 
 
Figure 6. Comparison of the human (right) and mice (left) lung. 
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 The lungs of each species also differ in symmetry: a monopodial branching pattern for 
mice in contrast to a dichotomous branching pattern for humans. Mice also possess a 
relatively large airway lumen compared to humans (Gomes and Bates 2002). These 
geometrical differences and some physiological differences will affect the deposition of 
aerosols in the lungs of each species. In addition to the existence of geometrical 
differences between human and murine lungs, there are also distinct differences in the 
pathology, physiology, and histology. The symmetry and size of the branching in the 
lungs account for most of the geometrical differences. The relatively large size of the 
lumen in mice is likely in place to accommodate air resistivity induced by the rapid 
respiratory rate (250 – 350 bpm) required to maintain body temperature (Bennett and 
Tenney 1982). The distribution of submucosal glands is different than that seen in 
humans, present only in the trachea (Innes and Dorin 2001). Lastly, mice tend to have 
significantly higher numbers of Clara cells, a morphologically distinct population of 
cells that have been identified for their importance in anatomical fortification against 
environmental exposures (Reynolds and Malkinson 2010; Irvin and Bates 2003).  
 
The more complex pathological, physiological, and histological differences will affect 
the nature of tumor formation and response to aerosolized nanoparticles in both species, 
which may be an important consideration for therapeutic treatment. With xenografting, 
genetic lesions of human lung cancer have been introduced into murine pulmonary tissue 
to yield lung tumors with similar characteristics to those found in humans. In addition, 
transgenic models have allowed for the assessment of oncogenes in tumor origination 
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and development by focusing their expression in a subset of lung epithelial cells 
(Meuwissen and Berns 2005; Shaw, Kirsch, and Jacks 2005). The superiority of animal 
models with grafts of tumor material (xenogeneic or syngeneic) over spontaneous tumor 
models is debatable; however, the use of these models has provided some significant 
advancements in preclinical studies, especially those of childhood cancer treatments, 
despite the lack of reliability or prediction of effect in clinical cancers (Kellar, Egan, and 
Morris 2015; Morton and Houghton 2007). Murine models altogether possess many 
advantages to other models such as human genome similarity, proven efficacy in the 
validation of drug targets and dosage schemes, cost-effectiveness and reproducibility, 
and large–scale phenotyping (Vandamme 2014). 
 
 Particle Deposition Mechanisms 
The treatment efficacy of aerosolized drugs is dependent on the dose deposited beyond 
the oropharyngeal region at the region of interest or targeted tissue, as well as the 
distribution of the drug in the lungs (uniform or not)  (Fernandez Tena and Casan Clara 
2012). The deposition of particles in the small airways gets maximum attention from 
pharmaceutical companies (Fernandez Tena and Casan Clara 2012). Deposition of 
aerosols in the airways can occur via inertial impaction, gravitational sedimentation, or 
Brownian motion (diffusion) (See Fig. 7)  (Dhanani et al. 2016). The modality of 
deposition is dependent upon many factors including size of the particles, speed, and 
turbulence. For example, at the alveolar level the minimal air velocity means there will 
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be no deposition by impaction and otherwise deposition will occur by sedimentation and 
diffusion (Lourenço 1982). 
 
 
Figure 7. Mechanisms of particle deposition in the airways. Depending on the diameter 
and velocity of the particle the mechanisms are inertial impaction, gravitational 
sedimentation, and diffusion. 
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 Clearance Mechanisms 
Once particles are deposited in the lungs, the presence of particles results in two 
pathways, retention and clearance. Retention is the tendency of particles to remain in 
pulmonary airways. Retention is dependent upon the physiochemical properties of the 
particles in the aerosol, the regional deposition of the particles in the lungs, and even the 
clearance mechanism involved. This is the same context as retention in the tumor, which 
is why clearance of nanoparticles may be a good thing, to prevent damage of normal 
lung tissues if retention of the nanoparticles is biased toward the tumor. Contrary to 
retention, clearance is the anatomical tendency to remove undesirable particles from the 
lungs of which there are multiple mechanisms. The efficient elimination of soluble and 
insoluble particulates inhaled and deposited in the respiratory tract is necessary to keep 
the mucosal surfaces clean and functionally intact (Isawa et al. 1984). Clearance 
mechanisms are important to mention because it may explain the translocation behavior 
of the nanoparticles following the aerosol deposition in the lungs. 
 
1.17.1.       Clearance via the Mucociliary Escalator 
The first line of defense for the respiratory system and the dominant clearance 
mechanism of the tracheobronchial region or the conducting zone is mucociliary 
clearance (Isawa 1994). The mucociliary escalator, as this clearance mechanism is 
termed, consists of continuous, rhythmic coordinated beating of cilia on the bronchial 
wall epithelium moving two fluid layers, periciliary fluid and a mucus “gel” layer 
towards the larynx where it can be swallowed (Oberdörster 1988). There are close to 200 
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fully functional and developed cilia grow on each airway epithelial surface from the 
trachea down to the terminal bronchioles (Isawa 1994). These cilia are roughly 6-7 m 
with a 1-m diameter and coordinated their rate of motion at 1000 beats per minute or 
10-15 Hz (Isawa 1994; Joseph, Puttaswamy, and Krovvidi 2013). This motion transports 
contaminant particles upon viscous capture sustained by the mucus composed of the gel 
and periciliary layers produced by goblet cells that lines the tracheobronchial region. The 
duration of obligatory removal of particles using this clearance mechanism is on the 
order of hours (2-3), even less if the particles are administered at a low dosage and prove 
to be irritants, and possibly more if administered in high dosages. 
 
1.17.2.       Pulmonary Alveolar Macrophages 
In the alveolar lung regions, the clearance mechanism of particulates has been shown to 
involve pulmonary alveolar macrophages (PAMs). PAMs have also been shown engulf 
particles and translocate them to the mucociliary escalator, lymphatic or 
venous/circulatory system for removal  (Joseph, Puttaswamy, and Krovvidi 2013). The 
destination of translocation is determined by the solubility of captured particles. Soluble 
substances can permeate the alveolar membrane where they are translocated via the 
venous system. It is hypothesized that nanoparticles will qualify as soluble particle and 
will thus appear in the venous system. For one such reason, PAMs have shown the 
capability to increase dissolution of metal oxides, potentially due to the low pH of their 
phagolysosomes (Lundborg, Lind, and Camner 1984).  Insoluble substances are likely to 
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be transferred to the lymphatic system and the duration of obligatory removal of these 
particles is on the order of months to years.  
 
1.17.3.       Particle Translocation 
20 nm iridium nanoparticles were reported to translocate from the lung surface into 
pulmonary tissue such that they could be subject to lymphatic drainage and venous 
incidence resulting in migration to secondary organs. This is because phagocytes may 
also transport the particles from the lungs to the lymph nodes for presentation to T 
lymphocytes (Lehnert, Valdez, and Stewart 1986). This would explain why healthy 
patients treated with conjugated-PEG agents also have been shown to potentially form 
antibodies against PEG as well (Garay et al. 2012). Even though relatively small 
amounts, some particulate translocation resulting in presence in the vein was also 
reported in studies using TiO2 nanoparticles (Semmler et al. 2004; Semmler-Behnke et 
al. 2007). However, lymphatic drainage was not assessed during these studies (Semmler 
et al. 2004; Semmler-Behnke et al. 2007). While 10% of the iridium nanoparticles 
administered were shown to translocate across the secondary organs, skeleton, and soft 
tissue (Semmler-Behnke et al. 2007)), it could be argued that delivery technique and 
how the nanoparticles were functionalized would affect this translocation significantly. 
The functionalization technique, if any, used for the iridium particles is not known 
(Geiser and Kreyling 2010). Translocation while potentially important in drug delivery 
studies is not necessary when imaging the lung tissues. The delivery method proposed 
here utilizes suspended AuNPs in a fluid solution that is the delivery agent to be 
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aerosolized.  
 Models  
Several models based on experimental results have been developed to model deposition. 
These include the Human Respiratory Tract Model from the International Commission 
on Radiological Protection (ICRP) and the National Council on Radiation Protection and 
Measurement (NCRP). These models are typically very similar in their deposition curves 
except for discrepancies found in the ultrafine particle range < 1-2 pm [63]. A java-based 
application known as Multiple-Path Particle Dosimetry Model (MPPD) performs 
calculations to yield an extensive amount of information regarding deposition influenced 
by parameters discussed previously using the human respiratory tract models (HRTM) as 
well as characterized murine models [64].  
 
To determine the efficacy of these nano-therapies, a well-characterized human 
orthotopic model of osteosarcoma lung metastasis has been developed to carry out in 
vivo evaluations with a focus on evaluating the mechanisms by which the nanoparticles 
improve the efficacy of cancer therapy as compared with the current formulations used 
clinically. Due to the complexity of cancer metastasis and unknown biodistribution and 
pharmacokinetics of these nanotherapeutics when dosed to the lung, an in vivo model is 
necessary to explore the processes that affect chemotherapeutic efficacy. Mice are the 
smallest generally accepted model for cancer biology that can be infected with human 
cancer cells and demonstrate metastases.  
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NOD/SCID IL-2-Receptor-gamma deficient -/- (NSG) mice will be used for this study, 
which are among the most immunodeficient mice available. Their severe combined 
immune deficiency mutation (SCID) and IL-2 receptor gamma chain deficiency yields a 
high success rate for xenograft implantation and metastasis. These animals have a retail 
price of approximately $100 and often are subject to shortages that severely limit 
experimental planning. Thus, to reduce costs overall and to retain better control over 
animal availability, all animals were obtained from mouse colonies already established 
by Dr. Wooley at TAMU, which produced up to 40 mice per month, including frequent 
“refreshing” of the colony with new, young breeders, since NSG mice are less fecund 
than conventional animals. Every effort was made to limit the breeding of experimental 
animals only to those needed for the study. 
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1.        Production of Radioactive 198Au Gold Nanoparticles 
Production of 198Au was carried out at the Texas A&M University Nuclear Science 
Center (NSC) in collaboration with Zaher Hamoui (Hamoui 2015). Briefly, 10 mg of 
high-purity gold (III) chloride trihydrate (HAuCl4) (Sigma Aldrich, St. Louis, Mo) in 
solid form was irradiated at the NSC for a minimum period of 4 h. Neutron activation of 
197Au resulted in the production of 198Au via the reaction 197Au(n,γ)198Au. The thermal 
neutron cross-section is approximately 4916 barns. The activated solid sample was 
transported to our labs using a compact shipment system for radioactive material (Model 
001-724, Biodex Medical Systems, Shirley, New York). Upon receipt of the sample, a 
high-purity germanium (HPGe) detector (Canberra Industries, Meridian, CT) was used 
to assess the purity of 198Au and the presence of potential radioactive impurities or 
contaminants. A dose calibrator (ATOMLAB 500 Dose Calibrator, Biodex Medical 
Systems, Shirley, NY) was used to assess the net activity of the radioactive sample. The 
activity levels of 198Au received varied considerably, depending on irradiation time and 
elapsed time for delivery. The radionuclide 198Au decays via beta particle emission and 
has a physical half-life of 2.6947 days with an average beta particle energy is 0.311 
MeV.  
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Radioactive AuNPs were produced using the Turkevich method (Kimling et al. 2006) as 
described by Kumar, et. al. (Kumar, Aaron, and Sokolov 2008) and Frens et. al. (Frens 
1973). Briefly, 1 ml of a 12.7 mM 198Au chloroauric acid solution was added to 49 ml of 
deionized ultra-filtered (DIUF) H2O in a clean 100 ml three-neck round-bottom flask 
fitted with a stir bar and reflux condenser (See Fig. 8). To this solution under reflux was 
added 0.94 ml of 38.8 mM trisodium citrate. The solution turned cherry red in ca. 2-3 
min, after which refluxing was continued for 10 min, producing 50 ml of highly 
spherical, mono-disperse gold nanoparticles between 15 to 30 nm in diameter, depending 
on chloroauric acid concentration. Particles were characterized by TEM and UV-Vis 
spectroscopy. Alteration of the nanoparticle size can be performed by manipulating the 
timing of trisodium citrate addition to the flask (Frens 1973). Nanoparticles were found 
to be stable for several months if stored at 4°C. The total activity per unit volume 
(µCi/ml) was estimated using a dose calibrator (AtomLab 500, Biodex, Inc.). 
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Figure 8. Experimental apparatus to produce gold nanoparticles: (1) heat block with 
round bottom insert for heat transfer purposes; (2) 100 ml round bottom flask (3-neck), 
containing stir bar and reactants; (3) reflux column; (4) charcoal in cotton to act as a 
filter; (5) cold water inlet for reflux column; (6) reflux water outlet; (7) hot plate. 
 
Functionalization of the AuNPs was also carried out. PEG modification, or PEGylation, 
is one of the most commonly used surface modification methods for gold nanoparticles. 
The PEG coating decreases the reduction of protein absorption and increases the stability 
of the AuNPs. It is important to note that PEGylation and/or protein conjugation to the 
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nanoparticles will cause a 3-5 nm red shift in the UV VIS spectra as the added layer of 
material affects the surface refractive properties (Kumar, Aaron, and Sokolov 2008). The 
PEG modification was carried out in our laboratory using the methods described by 
Cytodiagnostic (Tech Note #105). Briefly, 1 ml (0.25 nmol) of AuNPs coated with 
citrate (1.5x1014 particles/mL) was PEGylated by simple ligand exchange of citrate with 
a 1000-fold molar excess of carboxy-PEG5000-thiol (CM-PEG500-SH, Laysan Bio) in 
deionized water for 15 min. PEGylated carboxyl-terminal AuNPs (198AuNP-PEG-
COOH) were collected by centrifugal filtration at 5000 x g using 10 kDa MWCO 
Amicon Ultra-15 centrifugal filter units (Millipore) to remove excess unreacted PEG 
reagents, repeatedly washed with deionized water, and reconstituted in 0.5 ml MES 
buffer for addition of the immunoconjugate. 
 
Functionalization peptide of PEGylated radioactive gold nanoparticles with the cell 
penetrating was carried out using the method described by Cytodiagnostic. Briefly, 30 
mg of 1-Ethyl-3-carbodiimide hydrochloride (EDC) (Sigma, Cat# E1769) and 36 mg of 
N- hydroxysulfosuccinimide (Sufo-NHS) (Sigma, Cat# 56485) was mixed in 1 ml of 
MES buffer (Sigma, Cat# M5287) to form the EDC/NHS solution. Conde et al., has 
described in detail the above functionalization method. The advantage of EDC coupling 
is that it increases water solubility of PEG-AuNPs, which allows for direct bio-
conjugation without the prior use of an organic solvent to increase the stability of an 
active ester, such as N-hydroxysulfoxuccinimide (sulfo-NHS).  The addition of sulfo-
NHS also stabilizes the amine-reactive intermediate by converting it to an amine-
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reactive sulfo-NHS ester; therefore, it increases the efficiency of EDC-mediated 
coupling reactions (Conde et al. 2012). We first prepared a fresh EDC/NHS mix 
solution, as described before, in MES buffer at a concentration of 30 mg/mL and 36 
mg/mL, respectively. We then used 10-µL of PEGylated radioactive AuNPs and mixed 
with 10 µL of the EDC/NHS solution. The new solution was then incubated for 30 
minutes at room temperature.  One milliliter of PBS Tween (PBST) was added and 
vortexed subsequently. The solution was centrifuged at 6,500 g for 30 minutes and 
supernatant removed. 10 μl of human immunodeficiency virus type 1 trans-activating 
regulatory protein (HIV-1 Tat) (1 mg/mL in 1X PBS) was then added and solution 
sonicated in a water bath for 10 seconds. The mixture was then incubated for 2 to 4 
hours at room temperature with continuous mixing. 1 ml of PBST was added and again 
vortexed thoroughly. Subsequently, the solution was spun down by centrifugation at 
3,500 g for 30 minutes and supernatant removed. 50 μl PBS with 1% BSA was then 
added, followed by storage at 4 degrees until ready to use. Once radioactive and non-
radioactive AuNP were functionalized with HIV-1 Tat, they were ready to be used as 
later described with the real-time cell analyzer (RTCA) system.   
 
2.2.        Production of Radioactive 125I Integrated Gold Nanoparticles 
In addition to previous materials, mPEG-Thiol 2000 MW was purchased from Lysan Bio 
(Arab, AL, USA). Milli-Q water (18.2 MΩ) was used in all preparations.  2 mCi of 
Sodium Iodide-125 (Na125I) in 1×10-5 M NaOH solution, no carrier added, was obtained 
from Perkin Elmer Life Science, Inc. (Boston, MA, USA).  
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A stock preparation of gold solution was made by adding 55.5 mg of HAuCl4 to 500 ml 
of deionized water. A sodium citrate solution was made by adding 1.012 g of sodium 
citrate to 100 ml of deionized water (1% solution).  The citric acid solution was diluted 
to 1×10-5 M by taking 1 ml of initial solution and adding 9 ml of deionized water, and 
repeating the process four times. This technique was also used for the dilution of mPEG 
to 1×10-5 M as well. 
 
For synthesis of I-125 integrated AuNPs, 10 ml of the stock HAuCl4 solution was heated 
for approximately 10 minutes until reflux (visible boiling) while under continuous, 
vigorous stirring using a hot plate, aluminum reaction block, 3-neck round bottom flask, 
and reflux condenser. Then, the addition of 0.35 ml of the 1% sodium citrate solution 
was added to the mixture. Approximately 50 seconds after the addition of sodium citrate, 
10 μl of 1×10-5 M citric acid mixed with 10 μl of Na125I in 1×10-5 M NaOH, which 
equated to 100 µCi in the first obtained batch and 302 µCi the second obtained batch), 
was added to forming AuNPs. The activity of the 125I-AuNPs was measured using a dose 
calibrator (Biodex Medical Systems, NY). Once the 125I-AuNPs were PEGylated by 
addition of 50 μl 1×10-5 M mPEG-Thiol, they were shaken for 20 minutes using a vortex 
mixer. Then, three Eppendorf® centrifuge tubes containing nanopore filters, Nanosep 
10k Omega (Pall Corporation, Ann Arbor, MI) were filled with approximately 0.5 ml of 
the final product. Samples containing 0.5 ml of the gold nanoparticle solution were 
centrifuged at 1400 rpm for 10 minutes. Filters containing nanoparticles were separated 
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from the solvent, washed, and counted for radioactivity using a proportional counter. 
The solvent was also counted for radioactivity separately.  
 
2.3.        Non-radioactive Iodine Nanoparticle Synthesis 
To characterize the nanoparticles and perform TEM Imaging, non-radioactive iodine 
nanoparticles (Au-I-NPs) were made as well. First, 10 ml of the stock Au (III) chloride 
tri-hydrate solution was heated for approximately 10 minutes until reflux (visible 
boiling) while under continuous, vigorous stirring using a hot plate, aluminum reaction 
block, 3-neck round bottom flask, and reflux condenser. Then, 0.35 ml of the 1% sodium 
citrate solution was added to the mixture. This was followed by 0.25 ml of 1×10-5 M 
non-radioactive sodium iodine solution in 1×10-5 M NaOH solution and 0.25 ml 1×10-5 
M citric acid as a homogenous mixture, at various independent time intervals ranging 
from 0 to 180 seconds each time the gold nanoparticles with iodine were synthesized. 
The mixture was refluxed further for 5 minutes and allowed to cool off the hotplate.  
 
A mimetic of the 125I using the nonradioactive nanoparticles was also used for the animal 
imaging. First, 10 ml of the stock Au (III) chloride tri-hydrate solution was heated for 
approximately 10 minutes until reflux (visible boiling) while under continuous, vigorous 
stirring using a hot plate, aluminum reaction block, 3-neck round bottom flask, and 
reflux condenser. Then, 0.35 ml of the 1% sodium citrate solution was added to the 
mixture. This was followed by 0.25 ml of 1×10-5 M non-radioactive sodium iodine 
solution in 1×10-5 M NaOH solution and 0.25 ml 1×10-5 M citric acid as a homogenous 
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mixture at 50 seconds. For animal imaging the non-PEGylated gold nanoparticles were 
then centrifuged, the supernatant removed, and the precipitate resuspended in 100 μl of 
1×10-5 M mPEG-Thiol and 400 μl of 1×10-5 M Cy5.5-PEG-Thiol (Biochempeg 
Scientific INC., Watertown, MA, USA). They were then shaken for 20 minutes using a 
vortex mixer.  
 
2.4.        Production of Radioactive 211At Integrated Gold Nanoparticles 
For the final radionuclide integrated AuNP synthesis, 211At from Michael Martin’s Ph.D. 
experiment was then obtained and incorporated into colloidal gold nanoparticles. 
Initially, all glassware was washed with Aqua Regia (3 parts 5 N HCl, 1 part 6 N HNO3) 
and then rinsed with twice-deionized water. Then, 10 ml of deionized water was brought 
to a boil in round bottom flask, which was followed by the addition of 0.2 ml of 12.7 
mM HAuCl4.  After recovery from a capillary tube by using a 38.8 mM sodium tricitrate 
solution, an aliquot of 35 μCi (approximately 100 μl after decay) was prepared. This 
solution was added in the nanoparticle formation process described by the 125I 
experiment, however sodium citrate and the 211At were added together without the gap in 
time between the two. Following production, the nanoparticles were centrifuged at 
11,540 G for 10 minutes. The supernatant was removed, and the nanoparticles were re-
suspended and washed with fresh sodium citrate. The sample was spun again, and the 
nanoparticles were re-suspended in 100 μl of sodium citrate. 
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2.5.        Nanoparticle Characterization  
The nanoparticles produced for this research were compared with commercially 
available standards obtained from CytoDiagnostics, Inc., which came with a certificate 
for nanoparticle size and concentration. To find the size of the gold nanoparticles, each 
sample was measured using the Thermo Scientific NanoDrop 2000C spectrophotometer 
(See Fig. 9A). From each sample, 1 ml was pipetted into a cuvette and measured to 
produce absorbance spectra as a function of wavelengths. The wavelength for each 
sample was compared to the standard and showed strong correlation. The absorbance 
peaks were recorded for the calculation of the sample concentration.  The correlation 
between peak absorbance and nanoparticle size was plotted and fitted to a quadratic 
equation (See Fig. 9B). In this manner, it was possible to assess the average particle size 
from any of our experiments producing radioactive gold nanoparticles.  
 
 
Figure 9. (A) UV-Vis absorbance as a function wavelength (nm) for different AuNP 
standards of 5, 10, 15, 20, 30, 40, 60, 80 and 100 nm in diameter obtained using a 
spectrophotometer (NanoDrop 2000C, Thermo Scientific, Inc.). (B) Absorbance peak as 
a function nanoparticle diameter obtained using different AuNP standards of 5, 10, 15, 
20, 30, 40, 60, 80 and 100 nm. The relationship found was 𝐴 = 5.1602 × 102 +
1.1918 × 10−1 × 𝐷 + 4.5615 × 10−3 × 𝐷2 with a correlation coefficient of R = 
0.99905. Adapted with permission (Hamoui 2015). 
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The concentration of gold nanoparticles was calculated using the Beer-Lambert law 
expressed as:  
 𝐴 = 𝜀 ∙ 𝑏 ∙ 𝐶 (1) 
where ε represents the extinction coefficients , b that is the path length (cm), 
and C is the concentration in the sample expressed in molar concentration (M), and A is 
the absorbance peak. The extinction coefficients, ε, were determined previously in the 
literature using UV-Vis spectroscopy of nanoparticles of different sizes and surface 
ligands (see Fig. 10A) (Liu et al. 2007).  With consideration that the surface ligand was 
trisodium citrate and the path length of our spectrophotometer we can set b = 1 cm.  The 
nanoparticle concentrations from our produced results were calculated using Eq. (1).  
The nanoparticle concentrations were then compared to standards supplied by 
CytoDiagnostics, INC (see Fig. 10B).  
 
 
 
M-1  cm-1( )
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Figure 10. (A) The extinction coefficient,  as a function of nanoparticle diameter, d, 
was previously estimated by Liu et al., (Liu et al. 2007). Therefore, this estimation was 
compared with those calculated using the standards supplied by CytoDiagnostics, Inc. 
(B) Then a comparison between gold nanoparticle concentrations obtained from 
standards versus those calculated using the extinction coefficient, , given by the 
equation established from Liu et al., (Liu et al. 2007). The difference between our 
standards and those calculated were within reasonable range of each other. Adapted with 
permission (Hamoui 2015). 
 
Further size characterization and image acquisition of the gold nanoparticles was 
performed utilizing TEM. TEM was performed using an H-7650 (Hitachi, Tokyo, Japan) 
FEI Tecnai G2 F20 Super-Twin. The H-7650 is a 200 keV model with a ZrO2/W (100) 
Schottky Field emitter and an S-Twin objective lens.  AuNP samples were prepared by 
dropping 10-μl of solution on a copper TEM grid (Cat. N0. 71150, Electron Microscopy 
Science). Images were acquired using an automatic calibration of the microscope and a 
Charge-Coupled Device (CCD) (2k×2k CCD camera). 
 
Furthermore, characterization of the stability of 125I gold nanoparticles were tested by 
taking three 0.9 ml samples and allowing them to open air dry under a radiological fume 
hood for 4 days and examining loss of activity over time. Second, the non-radioactive 
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(10, 250, and 500 μl of 1×10-5 M sodium iodine solution in 1×10-5 M NaOH solution) 
and radioactive samples were characterized for their agglomeration in fetal bovine serum 
(FBS) from VWR (Pro. NO. 1400-100, Radnor, PA) and phosphate buffered saline from 
Lonza (Walkersville, MD). 
 
2.6.        Nebulizer System Design: 
The mouse nebulizer system requires certain key attributes for its efficacy. To ensure 
distribution throughout the functional pulmonary parenchyma of mouse lungs, a large 
fraction of the aerosol needs be less than 1 micron in diameter.  This is accomplished via 
collaboration with AeroGen, Inc. using a mesh nebulizer specifically designed for mice. 
The mesh nebulizer used had a mass median aerodynamic diameter (MMAD) of 2.171 
with a geometric standard deviation (GSD) of 2.037. A cylindrical mouse bed has been 
designed to hold the nebulizer, which fits at the top where the flow is biased towards the 
mouse nose and mouth. This was accomplished by making the nebulizer holder cone-
shaped and pushing isoflurane into the system via independent ports in the back and 
removing flow from the system via slits near the mouth of the mouse to be used for 
removal of excess aerosol buildup and preventing condensation. Vacuum is also used to 
prevent contamination of the area around the mouse body. There was a thin latex sheet 
with a slit near the front of the nebulizer system so that the mouse nose and throat tightly 
fit into the system.  The mouse nebulizer system will be used as an attachment to the 
micro-PET/CT so that delivery and uptake could be imaged in real time. Modeling was 
performed in Solidworks CAD software and exported as a stereolithography file (STL).  
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2.7.        Manufacturing  
The exported STL file was then sent to the engineering innovation center at Texas A&M 
University. The 3D printer chosen was the Stratasys EDEN 260V, which has a build 
volume of 255 x 252 x 200 mm (10.0 x 9.9 x 7.9 in.) with a 16-micron layer accuracy 
and 7-micron dimensional accuracy. The materials chosen were a soluble support 
material, which could be removed with ultrasonic bath and/or water-jet, along with Objet 
VeroWhite, which is a rigid opaque material with 1.1-1.5% water absorption. Figure 11 
shows a rendering of the device to be used in the present studies. The device is made 
entirely from 3D printed VeroWhite Polyjet material. This material offers great 
resistance to fluid permeation and offers some of the highest resolution/surface finish of 
other 3D printing materials.  
 
These features are important considering this device is used with radioactive fluids and 
the device must not harbor any residual contamination after use. Another key feature of 
the device is the internalization of the airway channels for both the vacuum and 
anesthesia systems. This is a feature of both function and convenience. By internalizing 
the channels, the anesthesia can be more effectively directed to the mixing chamber to 
mix with the aerosolized nanoparticle solution. The device also features two cap inserts 
that can be removed to more effectively clean the exhaust channels. There are three 
exhaust channels, two that connect to the mixing chamber near the mouth and one 
connected to a charcoal filter typically utilized for isoflurane. There is also one that 
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connects out to the bed where the mouse lays that should be connected to a vacuum 
pump with a charcoal filter as will be discussed in a later section. 
 
 
Figure 11. Preliminary design of the mouse nebulizer (cross-sections) to be 
implemented with the micro-PET/CT. The AeroGen, Inc. nebulizer inlet is located on 
top the system and the anesthesia gas mixture inlet are on the back. A vacuum outlet 
allows for the clearance of the cavity to prevent condensation.  
 
2.8.        Atomizer and Particle Distribution 
There is a wide variety of methods used to produce aerosols. The proposed design for 
this research utilizes a piezoelectric mesh atomizer, which qualifies as a vibrating mesh 
small-volume nebulizer. The nose-only nebulization system features an AeroGen 
nebulizer, which contains a vibrating palladium mesh. There is a 5 mm diameter central 
aperture plate perforated with 1000 precision formed holes, vibrating at 128,000 
vibration per second, producing the particle sizes optimal for deep lung penetration.  
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AeroGen claims a MMAD of 1-5 µm for this device. The AeroGen Pro for example was 
calibrated by AeroGen to have a MMAD of 3.7 µm. The deposition efficiency 
comparison between the AeroGen Pro and traditional small volume nebulizers (SVN) 
has been examined and reviewed (Ari, Areabi, and Fink 2010). It can be seen from the 
graphics in some papers using the AeroGen Pro that the deposition in the lung is more 
ubiquitous and penetrates deeper for the AeroGen Pro than for that of traditional SVNs. 
AeroGen claims that it is capable of producing lung deposition of 17% compared to a 
standard SVN with 3% lung deposition. The distribution of particle sizes produced from 
mouse nebulizer from AeroGen, that is repackaged by Aeroneb, INC., and sold at 
Harvard apparatus is presented in figure 12 alongside the deposition fraction per particle 
diameter as calculated from the previously discussed MPPD  (Anjilvel and Asgharian 
1995; National Institute for Public Health and the Environment (RIVM) 2002). 
 
 
Figure 12. On the left is the particle-size distribution of aerosols produced by an 
AeroGen/Aeroneb, Inc. mesh nebulizer sold by Harvard Apparatus (Apparatus 2017). 
On the right is the aerosol deposition fraction vs particle size in mice obtained via 
simulations with Multiple-Path Particle Dosimetry Model (MPPD) software (Anjilvel 
and Asgharian 1995; National Institute for Public Health and the Environment (RIVM) 
2002). Head: animal head; TB: tracheobronchial tree; P: parenchyma. 
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2.9.        In-vivo/Ex-vivo Imaging Equipment 
The Bruker AlbiraSi® is a high performance, Full Field of View multimodal PET, 
SPECT, CT system. A diagram of the AlbiraSi® is provided in figure 13. 
 
Figure 13. Detailed diagram of the AlbiraSi®, images supplied by courtesy of Bruker 
PCI with permission. 
 
Some of the applications that the Albira system can provide are a deep insight into in 
terms of the underlying mechanisms of diseases and the effectiveness of new 
therapeutics are pharmacokinetics, pharmacodynamics, ADME, protein/gene expression, 
metabolic studies, toxicology, and perfusion studies. While, PET, SPECT, and CT 
imaging were the original purposes of the nose-only aerosol delivery system there is also 
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potential for its use in optical imaging. This potential is also stronger than its potential 
use with radionuclides as near-infrared (IR) and Far-IR probes can be used for 
significantly longer periods of time and build up a signal overtime when typical imaging 
radionuclides would have already decayed.  The optical imaging equipment utilized for 
these experiments was the Bruker In Vivo Xtreme® (See Fig. 14), which has four built 
in imaging modalities (fluorescence, luminescence, radioisotopic, and X-ray). NSG mice 
engrafted with bioluminescent detectable human osteosarcoma xenografts into their left 
tibia were used. These cells were also modified to express green fluorescent proteins and 
as such the lung metastases were capable of being imaged using bioluminescence. These 
compounds don’t require any excitation and are expressed in significantly higher 
quantities than what can potentially be delivered by injection, let alone nebulization. 
Therefore, optical imaging is the preclinical gold standard when imaging cancer 
metastases as no other modality can image them effectively at early stages.  
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Figure 14. Detailed diagram of the Bruker In-vivo Xtreme®, images supplied by 
courtesy of Bruker PCI with permission. 
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Fluorescent probes are also frequently utilized for confocal imaging. Like the fluorescent 
modality of the Bruker In Vivo Xtreme®, Confocal microscopy utilizes a laser to image 
thin slices of tissues or any sample material you are looking at. 
 
2.10. Integration 
Figure 15 illustrates the integration of the system with the complete assembly in the 
Albira Si®. While this was the original plan for the nebulizer system, the device can be 
used as a standalone inside of a fume hood with connections to anesthesia and outlet 
towards charcoal filter. A Fume hood was utilized for the optical imaging studies. 
 
 
Figure 15. The assembly of the device with vacuum and anesthesia lines connected in 
the rear and the AeroGen nebulizer mounted on top and integrated into the Albira Si. 
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2.11. Anesthesia System 
The device features an anesthesia supply connected via the two input leads on the rear 
end of the device. This supply features a variable isoflurane-oxygen mixture. The 
isoflurane mixture served as a mechanism to push the aerosol toward the nose of the 
specimen and to the vacuum. An interesting feature of the design is that utilizing the 
funnel design we used the anesthesia supply to spin the aerosol in the chamber toward 
the mouse nose keeping it from touching the walls or creating gaps of aerosol in the 
chamber. 
 
2.12. Mixing Chamber 
The mixing chamber of the device required significant consideration in the design of the 
geometry. Intuition mandated a funnel design that would attempt to reduce deposition, 
due to geometrically induced turbulence, of the aerosol on the walls of the mixing 
chamber. The origin of this turbulence would stem from the “hard-edge” geometry of a 
straight cylinder. The anesthesia system features two ports at the rear end of the device 
designed to “push” the aerosol through to the other end of the mixing chamber. 
Originally, these two ports consisted of an entire annulus with integrated blades intended 
to focus the aerosol to the other end of the mixing chamber. However, due to 
complications with the 3D printing process due to removal of soluble supports, the 
blades were abandoned and the annulus width shortened, allowing for soluble support 
removal. Even at distances relatively close to the atomizer, there is homogeneity in terms 
of mist velocity and spatial particle distribution. In addition, the generated particles seem 
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to be less prone to coalescence and the consequent polydispersity, which contrasts with 
jet nebulizers.  
 
2.13. Exhaust/Aerosol Removal System 
The device features a vacuum exhaust system that removes the excess aerosol from the 
surrounding environment in case there is leakage from the nose (See Fig. 16).  
Originally, there was a vacuum exhaust which regulated the flow of the aerosol to 
consistently pass in front of the nose of the rodent for sustained dosage. However. it was 
found that suction removed the aerosol to a degree that it was not breathed. It was also 
found that when the mouse’s nose was snuggly fit into the nose piece, pressure would 
push the aerosol down the lines to the charcoal filter without the need for vacuum. 
Therefore, only one outlet, which is used for air outside the aerosol compartment was 
used for this vacuum system. This feature is a key element in maintaining isolation of 
the specimen from radioactive contamination. In the event the aerosol leaks to the 
housing chamber with the rodent bed, the vacuum system will remove the impurities 
from this region though the outlets.  
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Figure 16. The vacuum system used during experimentation. This vacuum system 
would remove any potential leakage of fluorescent probe or radionuclide from the mouse 
housing portion of the nebulizer system. 
 
2.14. Physiological Monitoring  
The BIOPAC® physiological monitoring system is a feature of the Albira Si. This 
feature played a large role in characterizing the breathing pattern of the rodent 
specimens. It consists of an air-filled, foam-like device that can expand and contract 
under the pressure of the body of the mouse (See Fig. 17). The pressure changes inside 
the device provided readings that can be represented graphically. We were not able to 
use this throughout these preliminary experiments but it will be incorporated into future 
models for respiratory gating. 
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Figure 17. This figure portrays the BIOPAC respiratory gating detector. This detector 
will allow monitoring of the mouse breathing and how much aerosol is being delivered 
based on the breathing pattern. 
 
2.15. Containment & Isolation System 
The containment/isolation system of the therapeutic device consists of a cylindrical 
acrylic exterior which should be airtight and capable of displacing all radioactive 
aerosols from the region. Failure to maintain isolation would result in contamination of 
the region surrounding the rodent specimen thereby rendering imaging by the Albira Si 
ineffective and potentially useless. One key component is that when the bed system is 
sealed properly the vacuum system will pull the air from around the mouse and simulate 
a negative pressure system. When the mouse’s nose is secured properly the internal 
chamber acts like a positive pressure system to remove excess aerosol as well, so one 
can observe fluid going towards the charcoal filter. 
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2.16. Cytotoxicity 
A label-free RTCA was used to assess cell growth and cell-mediated toxicity of 
cytotoxic agents to attached cells. The xCELLigence RTCA DP analyzer (ACEA 
Bioscience, Inc. San Diego, CA) uses impedance measurement to assess the real-time 
response of attached cells to x-ray radiation, chemotherapeutics, and 198AuNPs on SKBr-
3 cells. The system has three plates and each plate has 16 wells that are continuously 
monitored by the system, providing a real-time cell index response as a function of time. 
The cell index (CI) response has arbitrary units. Using experimental controls, the 
response of a cytotoxic agent can be estimated as a function of time. This system 
supersedes the use of the commonly used clonogenic assay (Franken et al. 2006), which 
only determines the potential for proliferation of cell in vivo as a function of absorbed 
dose or molar concentration. 
 
The RTCA system requires the determination of an optimal number of cells for seeding 
(per well) as to allow such cells to proliferate for a period time before treatment with a 
cytotoxic agent. To assess the optimal seeding per well, an initial experiment was carried 
out using various seeding numbers (3300, 5500, 10000, and 25000 cells per well). Once 
the optimal seeding number was established for SKBr-3 198Au gold nanoparticles were 
tested for their cytotoxicity. 
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2.17. Mouse Imaging and Nebulizer System Characterization 
To establish an orthotopic xenograft mouse model of osteosarcoma, NOD/SCID IL2-R-
gamma -/- mice (The Jackson Laboratory) aged 4-6 weeks (males and females) were 
injected in their left tibias while under isoflurane anesthesia (1-2% v/v in pure O2) with 
a 10 µl PBS suspension of SJSA-1 cells (ATCC) constitutively labeled via lentiviral 
transfection with firefly luciferase and GFP, for tracking the tumor progression in vivo 
and location for histology ex vivo. For the AuNP and micelle studies the injection dose 
of SJSA-1 cells was 50,000 cells. 
 
For this procedure, a 27 Ga syringe needle is drilled into the proximal epiphysis of the 
tibia and guided down the tibia about mid-way to the diaphysis, where the suspension is 
injected.  Five days following engraftment, the mice were given intraperitoneal 
injections of 0.15 ml of 30 mg/ml D-luciferin potassium salt (Bioworld) and imaged for 
optical signal 15 minutes later using a small-animal optical imaging cabinet (Xtreme In 
Vivo, Bruker).  X-ray images of the mice were also taken to provide anatomical 
reference.  Baseline metastatic burdens in the lungs were then determined by measuring 
the signal intensity in the chest region of each mouse.  The mice were then assigned to 
one of three groups, determined randomly but matching for similar average baseline lung 
signals among groups. 
 
For the AuNP studies mice were nebulized with 2 ml of nonradioactive iodine AuNP or 
non-iodinated AuNP suspensions under isoflurane anesthesia lasting no more than 20 
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minutes on Days 22, 23, and 24 from the time of tumor engraftment (See Table 1). For 
the micelles mice were nebulized on Days 6, 7,8,9,10, 12,14, and 17 with 1 ml of either 
PBS only, 0.18 mg/ml dimerized paclitaxel prodrug dissolved in PBS with 5% DMSO, 
or 0.18 mg/ml dimerized paclitaxel loaded in Near IR-labeled PEG-b-PGC micelles in 
PBS. Only images were obtained from the micelles to characterize the nebulization 
system and PBS was used for both controls. Isoflurane anesthesia was maintained 
throughout nebulization at a low level (0.5 - 1% v/v in pure O2) to prevent the mice from 
moving too much during the procedure and getting exposed to the mist on their eyes or 
skin. Directly following nebulization, the mice were imaged again to obtain the 
fluorescence signal from the nanoparticles (excitation 760 nm / emission 820 nm for 
micelles and excitation 690 nm / 750 nm emission for AuNPs) in the lungs. Nebulization 
was performed for three consecutive days and then re-imaged for fluorescence signal. 
 
Table 1. The mice were split into two groups either having the AuNPs or the Au-I-NPs 
and are categorized below. 
 
ANIMAL 
IDENTIFICATION 
AuNPs Au-I-NPs 
170907A 170907B 
170907F 170907D 
170907K 170907E 
170907I 170907J 
 
On Day 19 for the micelles and Day 28 for the AuNPs the mice were euthanized via CO2 
asphyxiation and dissected to recover the lungs and other organs.  The lungs were then 
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inflation fixed by intratracheal instillation 4% formalin in neutral buffered saline for 30 
minutes. This was followed by immersion in 15% sucrose/PBS mixture for 30 minutes, 
and then 30% sucrose/PBS mixture for another 30 minutes. The lung tissue was then 
split into 5 distinct lobes, placed in cryomolds with a drop of optimal cutting temperature 
(OCT) media (Tissue-Tek®, Sakura® Finetek). The distinct lobes were the superior lobe 
(SL1), middle lobe (ML2), inferior lobe (IL3), post-caval lobe (PCL4), and left lung 
(LL5). They were then imaged ex vivo with optical imaging at the previously mentioned 
laser levels (See Fig. 18). Then the lobes will be submersed in OCT and snap frozen in 
dry-ice/ 100% ethanol slurry for cutting and imaging using confocal microscopy. 
 
 
Figure 18. This figure depicts how each lobe of the mouse lungs was characterized 
before being split up for imaging. 
 
For microscopic analysis, the frozen tissue was sliced into 20 micron sections using a 
cryostat (Cryotome®, ThermoFisher Scientific) at -15 °C.  The sections were mounted 
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onto slides and cover-slipped with optical medium (Fluoromount-G, ThermoFisher 
Scientific).  Confocal-microscope imaging (Fluoview FV1000, Olympus) was performed 
to evaluate the distribution of nanoparticles within the lung tissue with reference to the 
GFP-labeled tumors.  Images were acquired using a 10x air objective with laser 
excitations at 488 nm (GFP) and 635 nm (NIR) along with a transmission light detection 
unit and Nomarski DIC to visualize the lung structures in high detail.  Imaging of the 
entire lung slices was achieved with a motorized XY stage (Prior Scientific) and the 
Olympus FV10 software. A multiarea time lapse protocol in the Olympus Fluoview® 
software was used for drawing regions around each lobe of the mouse lungs and imaging 
with an aspect ratio of 640 by 640.  Mosaic stitches of the entire lung sections were 
analyzed for intensity using ImageJ. 
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CHAPTER III 
RESULTS 
 
3.1.    SKBr-3 RTCA cell seeding experiments 
A cell seeding experiment was carried out to determine the optimal conditions for SKBr-
3 growth over an observation period to prevent the need to change the growth medium 
too early during a study (See Fig. 19). The RTCA system was thus seeded with densities 
of 3300, 5500, 10000, and 25000 cells per well. Figure 19 illustrates the cell index (CI) 
response as a function of time for a period of more than 190 h. The maximum CI 
achieved by these cells was estimated at 3.0 without exchanging the cell growth media.  
 
 
Figure 19. RTCA cell Index (CI) response as a function of time for seeding per well of 
3,300 (pink), 5,000 (blue), 10,000 (green) and 25,000 (red) per well. The optimal 
seeding was determined at 10,000 cells per well within a time lapse of less than 196 h. 
Reprinted from (Hamoui 2015). 
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The optimal seeding concentration was chosen to be approximately 10,000 cells per 
well. This would cause the CI to reach a value of 1.5 within 84 hours, thus allowing the 
assessment of potential cytotoxic response for CI < 1.5 or re-growth response for CI > 
1.5 past 84 hours without concern of well saturation or need to replace media less than 
three days after administration of the compound of interest. This concentration also 
offered the most consistent results suggesting some leeway in administration of cell 
concentration without significantly altering growth. Based on these results, future 
experiments were carried out at a seeding of 10,000 cells per well.  
 
3.2.    Estimation of number of 198Au radioactive atoms per nanoparticle 
Once radioactive nanoparticles were generated using the previously mentioned 
Turkichev method, the total activity per unit volume (µCi/ml) was estimated using a 
dose calibrator (AtomLab 500, Biodex, Inc.). When a sample of solid chloroauric acid is 
activated via the 197Au(n,γ)198Au reaction, only a fraction of the 197Au gold atoms are 
transformed into 198Au. Overall, the fraction of atoms that are transformed into 
radioactive gold is very small when compared to the total number of atoms of gold in the 
sample. This fraction heavily depends on neutron irradiation conditions, such as neutron 
flux (n cm-2 s-1), irradiation time, and decay (e.g., due to delay in shipment). The 
nominal neutron flux used to irradiate our samples at the Nuclear Science Center was 
approximately 1×1013 n cm-2 s-1. The specific activity of a radioactive sample was 
estimated using an HPGe detector. Specific activity is the total activity per unit mass of a 
compound (i.e. HAuCl4) and it is commonly expressed in MBq per mg.  
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The number of radioactive gold atoms (198Au) per nanoparticle follows the Poisson 
distribution and depends on the average nanoparticle size or average diameter of 
nanoparticles along with the specific activity. As a result, large particles may contain 
more radioactive atoms than small particles, and vice versa. The distribution of AuNP 
diameters obtained from TEM images (See Fig. 20) was used to carry out these 
calculations and convoluted with the Poisson distribution.  
 
 
 
Figure 20. TEM figures of in-house produced AuNPs and schematic representation 
showing the functionalization of a radioactive AuNP using PEGylation methods and 
attachment of the cell penetrating peptide HIV-1-Tat. Reprinted with permission 
(Hamoui 2015).   
 
The average activity (Bq) per nanoparticle, ANP, is the product of the nanoparticles mass 
multiplied by the specific activity, SA: 
                                            𝐴𝑁𝑃 = 𝑉𝑁𝑃 ∙ 𝜌 ∙ 𝑆𝐴 =
4
3
𝜋𝑟𝑁𝑃
3 ∙ 𝜌 ∙ 𝑆𝐴                                        (2) 
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where  is the radius of a nanoparticle. The average number of radioactive atoms per 
nanoparticle, , is then given by:
 
 
 𝑁𝑁𝑃 =
𝐴𝑁𝑃
𝜆
 (3) 
where λ = 2.98×10-6 s-1 is the decay constant of 198Au. Thus, the average number of 
radioactive atoms increases with specific activity SA. The probability of number of 
radioactive atoms per nanoparticles with a specific radius is given by:  
 𝑃(𝑥) =
𝜇𝑥𝑒−𝜇
𝑥!
 (4) 
where  is the average number of radioactive atoms in a nanoparticle. Thus, the 
fraction of radioactive atoms as a function of SA for a nominal nanoparticle diameter of 
15.9, based on diameter averages of TEM images obtained using similar synthesis 
procedures, is given in Figure 21. 
 
rNP
NNP
m = NNP
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Figure 21. Depicted is a poisson distribution for the fraction or probability of having a 
certain number of radioactive atoms of 198Au per nanoparticle as a function of SA (MBq 
mg-1). The potential fraction of nanoparticle that will have zero radioactive atoms 
decreases exponentially as a function of SA. The nominal diameter for the nanoparticles 
used in these calculations was 15.9 nm. Adapted with permission (Hamoui 2015). 
 
Once radioactive nanoparticles were produced, it was then possible to assess the 
distribution of radioactive atoms per nanoparticle in each solution using an estimate of 
the average diameter, nanoparticle concentration (nanoparticles per milliliter), and 
activity concentration per unit volume of the sample. The average diameter can be 
calculated using the UV-Vis method; the concentration of nanoparticles can be estimated 
using the optical absorption, and the activity concentration (not specific activity) using a 
dose calibrator.  Therefore, we can write:  
 𝜇 =
1
𝜆 (𝑠−1)
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛,𝐴 (𝐵𝑞 𝑚𝑙−1)
𝑁𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛,𝑁𝑃 (𝑁𝑃𝑠 𝑚𝑙−1)
 (5) 
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and based on the Poisson distribution, the fraction of nanoparticles with zero 
radioactivity atoms is given by 𝑃(0) = 𝑒−𝜇 , similar estimates can be made for one 
radioactive and multiple radioactive atoms per nanoparticle. 
 
These calculations were required to assess how many radioactive atoms and 
corresponding decays would occur per nanoparticle. Each radioactive decay will emit 
certain characteristic radiative emissions based on the decay scheme of 198Au. For a 
given nanoparticle, each radiative emission will occur in the same cell when the 
nanoparticle is entrapped in the cell surface or internalized in the cytoplasm, yielding a 
higher dose per tumor cell.   
 
3.3.  Characterization of 198AuNPs 
To characterize the produced radioactive gold nanoparticles, 1 ml of the resulting 
solution was used to assess the surface plasmon resonance using the NanoDrop 2000C 
spectrophotometer. Figure 22A shows the UV-Vis spectrum as a function of photon 
wavelength. The absorbance peak was measured at 525 nm, which corresponded to 
particle size of 32.9 nm. The measured absorbance peak at 525 nm was 1.34 resulting in 
a concentration of 2.29×1011 (NP/ml). Using the dose calibrator, the measured activity of 
the 1 ml sample was 480 (µCi/ml). The estimated number of 198Au atoms per 
nanoparticle was 25.9, which resulted in a negligible zero-fraction (𝑃(𝑋 = 0) = 𝑒−25.9.  
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TEM was used to characterize the shape, size, and particle number of non-radioactive 
AuNP. Reproducible synthesis of AuNP was confirmed by TEM analysis. Image 
analysis for nanoparticle diameter was carried out using the software program ImageJ 
(Schneider, Rasband, and Eliceiri 2012). A narrow distribution for AuNP was obtained 
with a range between 11.6 and 23.5 nm and an average diameter of 15.9 nm (Fig. 22B) 
 
 
Figure 22. In this figure (A) is the UV-Vis spectrum of radioactive gold nanoparticles, 
and (B) is TEM image analysis, which demonstrated a narrow particle size distribution, 
with a size range between 11.6 and 23.5 nm and an average diameter of 15.9 nm. The 
surface plasmon resonance had a maximum peak observed around 525 nm with an 
absorbance of 1.341 corresponding to a gold nanoparticle diameter of 32.9 nm at a 
concentration of 2.29×1011 NP/ml. A lognormal distribution was fitted to the data which 
depicted a negative skew of the measured distribution towards larger size nanoparticles. 
In collaboration with Hamoui with permission (Hamoui 2015). 
 
3.4.    Cytotoxicity of 198AuNPs and 198AuNPs-HIV-1 Tat 
The cytotoxicity of radioactive 198AuNPs was assessed using the RTCA system to 
examine the effect on SKBr-3. We seeded 10500 tumor cells per well and after 30 hours 
of incubation, HIV1-Tat functionalized and non-functionalized 198AuNP with different 
activities were added into the wells in quadruplicates. The activities used were 50, 100, 
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500, 1000, and 1500 kBq. The experimental arrangement was as follow; 1) SKBr-3 cells 
used as a control, 2) SKBr-3 cells treated with AuNPs (non-radioactive), 3) SKBr-3 cells 
treated with AuNP HIV-1 Tat (non-radioactive), 4) SKBr-3 cells treated with 198AuNPs, 
5) SKBr-3 cells treated with 198AuNP HIV-1 Tat.  
 
Figure 23 presents the cell growth response as a function of time for the different 
experimental arrangements as described above. The incubation period was for 12 hours 
and after that the medium was exchanged and cells were washed once to remove any 
non-internalized nanoparticles. However, it is important to mention that we were not 
able to determine the fraction of activity that was retained in the wells after washing 
them with PBS. We expected that internalization of 198AuNPs-HIV-1 Tat will have a 
significant impact in cell growth; however, as observed in figure 23A, the growth profile 
of 198AuNPs and 198AuNPS-HIV-1 Tat was similar with a minimal reduction in CI by 
those treated with 198AuNPS-HIV-1 Tat. The cell response to non-radioactive AuNPs-
HIV-1 Tat was like that of controls; this indicates that the non-radioactive AuNPs-HIV-1 
Tat had no effect on the SKBr-3 cells growth, which corroborates many studies that 
AuNPs have little cytotoxic capability on their own (Connor et al. 2005; Shukla et al. 
2005; Villiers et al. 2010).  
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Figure 23. (A) Normalized Cell Index as a function of time for SKBr-3 cells exposed to nonradioactive AuNP (green line) and 
control (red line). (B) Normalized Cell Index as a function of time for SKBr-3 cells exposed to 198AuNPs-HIV-1 Tat with an 
activity of 50 kBq (green line) and 100 kBq (blue line), 198AuNPs with an activity of 50 kBq (pink line) and 100 kBq (brown 
line), and control (red line). (C) Normalized Cell Index as a function of time for SKBr-3 cells exposed to 198AuNPs-HIV-1 Tat 
(green line) and 198AuNPs (blue line) with an activity of 500 kBq and control (red line). (D) Normalized Cell Index as a 
function of time for SKBr-3 cells exposed to 198AuNPs-HIV-1 Tat with an activity of 1000 kBq (green line) and 1500 kBq 
(blue line), 198AuNPs with an activity of 1000 kBq (pink line) and 1500 kBq (brown line), and control (red line). The solid 
black lines represent the incubation time between the addition of the AuNP and the time when the medium was replaced. In 
collaboration with Hamoui with permission (Hamoui 2015). 
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In terms of activity, the cell growth response to 50, 100, and 500 kBq of 198AuNPs and 
198AuNPs-HIV-1 Tat was not significant as shown in Figure 23 (B and C); the cell 
growth response was comparable to controls. Interestingly, 50 kBq and 100 kBq may 
show a promotion of cellular growth adding strength to theories that at low doses there is 
competition between death, repair, and defense mechanisms. However, the cell death 
response to 1000 and 1500 kBq of 198AuNPs and 198AuNPs-HIV-1 Tat was observed 
distinctly. This shows that doses below 1000 kBq were too low to yield a cell death 
response.    
 
The cell response to 198AuNPs-HIV-1 Tat and 198AuNPs with activities of 1000 and 1500 
kBq was initially observed in the slope of the spectrum. Following the exchange of the 
medium inside the wells, a decrease in the slope was observed. This showed that the 
cells duplication rate was slowed as a function of time.  The major observable effects of 
radioactive AuNP were seen after 150 h (~ 6 d), where the CI of the treated cells started 
declining with a very fast rate resulting in observed cell death afterwards, while the trend 
of the controls kept growing until reaching a plateau at 175 h (~ 7 d).  
 
3.5.    Determining Influence of Time on Iodine Addition  
We investigated the influence of time and stability of nanoparticles during their 
synthesis with the addition of non-radioactive NaI. Timing was found to be critical as it 
controlled the size distribution of nanoparticles and their aggregation. The diameters of 
the resulting I-AuNP at various time intervals were measured using UV-Vis, resulting in 
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a broad range of sizes. Figure 24 shows that AuNPs were partially size-stabilized at 
approximately 50 seconds after the addition of sodium citrate. Therefore, this was used 
as a threshold at which 125I can be added without a drastic destabilization of the surface 
charges of AuNPs leading to rapid aggregation.  
 
 
Figure 24. Estimated diameter of AuNPs using UV-Vis obtained with nonradioactive 
sodium iodine (NaI) added at different time points following after addition of sodium 
citrate during AuNP synthesis. Reprinted with permission (Clanton et al. 2017). 
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Following synthesis several 0.9 ml AuNP samples with approximately 11.5 µCi each of 
activity were taken from the reaction vial and allowed to dry under air in a radiochemical 
fume hood over a period of 4 days. Over the 4-day period, we found negligible loss of 
125I2 activity resulting from oxidation and sublimation.  The same was observed from the 
dry nanoparticles obtained from nanopore filter paper insert after centrifugation in an 
Eppendorf tube. The 125I was found to be associated with the nanoparticles on the 
nanopore filter paper and negligible radioactivity close to the background radiation was 
found in the supernatant.  
 
Solutions of control (no iodine added), 10 μl NaI, 250 μl NaI, 500 μl NaI, and 302 µCi 
Na125I were used to test the stability of our synthesized gold nanoparticles in fetal bovine 
serum and phosphate buffer saline (See Fig. 25). It appears that iodine has the capability 
of increasing the stability of gold nanoparticles in solutions of phosphate buffer saline. 
Phosphate buffer saline has previously been corroborated to induce aggregation of gold 
nanoparticles (Du et al. 2012). None of the nanoparticles seemed to aggregate in the 
presence of fetal bovine serum and no hindrance in stability was observed. No changes 
have been observed to this date (~8 days later) in either solution mixtures past 48 hours 
besides the 500 μl NaI solution beginning to settle at the bottom of tube. However, once 
agitated the sediment resuspended. In terms of Na125I nanoparticles the fetal bovine 
serum had no activity in the solution but there was activity in the phosphate buffered 
saline. However, it can be noted from figure 25 that there is an apparent alteration in the 
nanoparticles denoting aggregation. Future studies may need to look at adding non-
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radioactive iodine in conjunction with radioactive to increase the stability of 
nanoparticles in phosphate buffered saline. Just 10 μl of 10-5 M NaI in 10-5 M NaOH 
solution can prevent aggregation in phosphate buffered saline, which adds to the 
evidence that if iodine is added at the proper moment of AuNP synthesis then the AuNPs 
will be more stable. An interesting observation was that after centrifugation AuNPs 
without iodine could be pipetted out of solution without issue but AuNPs with iodine 
would continue to leak back into the solution as the pipette was being taken out. This 
concept may be an important consideration in other nanoparticle studies that are finding 
it difficult to produce stable nanoparticles in phosphate buffer saline or fetal bovine 
serum. 
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Figure 25. The solutions of the gold nanoparticle containing different quantities of 
iodine in fetal bovine serum and phosphate buffer saline are depicted. The larger the 
amount of iodine added the more stable the nanoparticles appear in phosphate buffer 
saline. Reprinted with permission from (Clanton et al. 2017). 
 
TEM imaging was conducted at the Texas A&M Microscopy and Imaging Center. For 
safety considerations, TEM was performed on the gold nanoparticles integrated with 
non-radioactive iodine to prevent contamination of the TEM. TEM images revealed that 
the synthesized AuNPs were roughly spherical (see Fig. 26) with an average diameter of 
20 nm. Unfortunately, Electron Diffraction Spectroscopy (EDS) and X-ray Diffraction 
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(XRD) were ineffective in assessing the iodine content in AuNPs as these modalities 
both have a detection limit of about ca.1% in atomic content. 
 
 
Figure 26. TEM image of AuNPs synthesized with non-radioactive iodine. The average 
diameter was 20 ± 5 nm (95% CI). Reprinted with permission from (Clanton et al. 
2017). 
 
3.7.    Activity distribution of Iodine Integrated AuNPs 
In our first experiment, we used a total net activity of 3.7 MBq (100 µCi) and 0.555 mg 
of pure gold. Using the previously mentioned Poisson equations for the number of 
radioactive atoms per nanoparticle, this resulted in a nominal µ = 2.77 for 20 nm 
nanoparticles. In our second experiment, we repeated with 1.7 MBq (46.7 µCi) and 11.2 
MBq (302 µCi) obtaining similar results. Figure 27 shows the Poisson distributions 
where the fraction of nanoparticles with no radioactive atoms was approximately 6% in 
the 100 µCi samples and 0% in 302 µCi samples.   
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Figure 27. This figure presents Poisson distributions assessing the fraction of 
radioactive atoms per nanoparticle. The average diameter of an AuNP was 20 nm. 
Reprinted with permission from (Clanton et al. 2017). 
 
The probability at time (t) that exactly a specified number of decays (d) per AuNP have 
occurred can be obtained by the binomial distribution:  
 𝑃(𝑑; 𝑡) =
𝑥!
𝑑!(𝑥−𝑑)!
(1 − 𝑒−𝜆𝑡)
𝑑
(𝑒−𝜆𝑡)𝑥−𝑑 (6) 
where d is the number of radioactive atoms that decay, t is the time after synthesis, λ is 
the decay constant of the radioactive atom in question, x is the population size of 
radioactive atoms per AuNP (same as the previously obtained Poisson distribution). 
When multiplied by the previously obtained Poisson distribution (independent 
probabilities), a probability density function can be obtained for a certain number of 
decays at a given time (t) for a certain number of radioactive atoms per AuNP (x).  
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 𝑃(𝑥 ∩ 𝑑; 𝑡) =
𝑒−𝜇𝜇𝑥
𝑑!(𝑥−𝑑)!
(1 − 𝑒−𝜆𝑡)
𝑑
(𝑒−𝜆𝑡)𝑥−𝑑 (7) 
This density function provides the basis for the microdosimetry of radioactive 
nanoparticles near sensitivity targets, including DNA, as previously described 
(Balagurumoorthy et al. 2012; Humm, Howell, and Rao 1995). 
 
3.8.     Astatine-211 Integrated Nanoparticles 
For the 211At integrated AuNPs, the supernatant and the samples were separated and 
measured utilizing the dose calibrator. The nanoparticles were found to have 28 µCi or 
approximately 80% retention of the initial activity. This established that the colloidal 
gold nanoparticles were successfully formed with radioactive 211At. The final solution 
was then placed in a cuvette and diluted to a volume of 1 ml. Utilizing UV-Vis 
spectroscopy, the wavelength and absorbance peak were measured to assess the nominal 
nanoparticle size and concentration. The measured wavelength was 525 nm with an 
absorbance peak of 0.8 (a.u.).  The nominal nanoparticle diameter was estimated at 35.1 
nm, which is consistent with preliminary results with non-radioactive nanoparticles. The 
estimated extinction coefficient was 8.45×109 M cm-1. Based on the Beer-Lambert 
equation, the resulting nanoparticle concentration was estimated at 5.7×1010 cm-3.  The 
total number of radioactive atoms in the nanoparticles was 3.88×1010 cm-3, which 
corresponds to a nominal µ of 1.47. The resulting distribution of radioactive atoms per 
nanoparticle is given in fugure 28.  
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Figure 28. Distribution of radioactive atoms per nanoparticle based on a nominal mean 
of µ = 1.47. The fraction of nanoparticles with no radioactive atoms was 0.23, and the 
fraction with one or more radioactive atoms was 0.77. 
 
3.9.     Characterization of Nebulizer 
As previously mentioned, the mesh nebulizer used in this mouse nebulization system had 
a mass median aerodynamic diameter (MMAD) of 2.171 with a geometric standard 
deviation (GSD) of 2.037, which was obtained utilizing a next generation impactor 
(NGI). Therefore, using the Hatch and Choate Relations: 
𝑑𝑚𝑒𝑑𝑖𝑎𝑛
(𝑞)
= 𝑑𝑚𝑒𝑑𝑖𝑎𝑛
(1)
exp (𝑞𝑙𝑛2𝜎𝑔)                                (8) 
Where 𝑑𝑚𝑒𝑑𝑖𝑎𝑛
(𝑞)
is the median diameter property distributed as, dq , q is the power of the 
diameter, 𝜎𝑔 is our previous GSD, 𝑑𝑚𝑒𝑑𝑖𝑎𝑛
(1)
 is the number-median aerodynamic diameter 
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(NMAD), 𝑑𝑚𝑒𝑑𝑖𝑎𝑛
(2)
 would be the surface-median aerodynamic diameter (SMAD) if that 
is the variable we want, and 𝑑𝑚𝑒𝑑𝑖𝑎𝑛
(2)
 would be our MMAD. As such we would find our 
NMAD to be 18.6 nm and our SMAD would be 4.9 nm. 
 
3.10.     Mouse Nebulization Studies 
Three days after nebulizing the AuNPs and Au-I-NPs the lungs were removed from the 
mice utilizing the fixation techniques previously described. Then, the lobes were 
separated as previously described in figure 18. These lobes were then fluorescently 
imaged using the Bruker In Vivo Xtreme (see Fig. 29). From these images, the 
backgrounds were removed and regions of interest were drawn around the lobes of the 
lungs and the pico-watts per mm2 of tissue was calculated (see Table 2 and Table 3). 
 
 
Figure 29. Ex Vivo imaging was performed on each lobe of the mouse lungs. In A and 
B, from top left to bottom right the lobes are arranged from superior lobe (SL1), middle 
lobe (ML2), inferior lobe (IL3), post-caval lobe (PCL4), and left lung (LL5). Signal of 
tape on right of each dish is reflectance. The settings were 690 nm for the excitation and 
750 nm for emission. A is the control mouse and B is 170907F. These images were set to 
minimum intensity of 300 and a maximum intensity of 800. 
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Table 2. The distribution of signal in sum intensity or counts per square centimeter for 
each lobe of the lungs for each mouse examined in this study. 
 
Table 3. The Sum of (Pico-Watts per square millimeter) signal normalized by the area in 
squared cm for each lobe, divided into AuNP or Au-I-NP delivery, of the lungs for each 
mouse examined in this study.   
SL1 ML2 IL3 PCL4 LL5 
CONTROL 83.03988 114.5477 93.9838 80.95804 97.61817 
AUNPS 170907A 112.385 117.1136 117.2932 110.8785 164.3623 
170907F 78.58665 123.3254 130.4085 112.1852 136.1836 
170907K 77.69798 112.9328 124.4919 99.62262 131.2132 
170907I 89.3363 115.6484 107.8404 109.3927 145.5393 
Average 89.50148 117.255 120.0085 108.0198 144.3246 
Standard 
Deviation 
16.1466 4.40197 9.724484 5.713151 14.61927 
AU-I-NPS 170907B 120.7044 152.084 149.7718 118.7661 182.7408 
170907D 75.6605 114.8547 116.115 100.3256 131.2176 
170907E 77.38314 114.54 118.4616 108.9188 156.1874 
170907J 82.49947 112.023 122.0568 109.0519 146.5378 
Average 89.06188 123.3754 126.6013 109.2656 154.1709 
Standard 
Deviation 
21.29402 19.18097 15.6391 7.535422 21.6443 
 
  
            
SL1 
ML2 IL3 PCL4 LL5 
CONTROL 293922.6 405445.8 332659.0 286553.9 345523.0 
AUNPS 170907A 397790.7 414527.9 415163.4 392458.5 581766.3 
170907F 278160.2 436514.5 461585.5 397083.4 482026.8 
170907K 275014.7 399729.6 440643.4 352617.8 464433.8 
170907I 316209.0 409341.6 381704.8 387199.4 515141.6 
Average 316793.7 415028.4 424774.3 382339.8 510842.1 
Standard 
Deviation 
57151.5 15580.9 34420.1 20221.9 51745.4 
AU-I-
NPS 
170907B 427237.6 538306.9 530122.7 420376.7 646817.7 
170907D 267803.0 406532.4 410993.1 355106.1 464449.3 
170907E 273900.4 405418.5 419299 385522.1 552831.0 
170907J 292009.8 396509.5 432024.3 385993.0 518675.7 
Average 315237.7 436691.8 448109.7 386749.5 545693.4 
Standard 
Deviation 
75370.9 67891.7 55355.1 26671.8 76610.7 
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Table 2 and 3 seem to show that Cy5.5-PEG-Au-I-NPs and Cy5.5-PEG-AuNP had 
roughly the same signal. 170907B gave us the strongest signal intensity and best overall 
images for this mouse during confocal imaging, giving us the highest signal intensity as 
well. It is also apparent that some of the lobes like SL1 that some mice did not have 
measurable signals above the background (possibly due to attenuation). This was also 
apparent for SL1 for in figure 29. 
 
After performing ex vivo imaging of the lung lobes they were frozen in OCT and sliced 
with the microtome. These slices were then placed on microscope slides and imaged 
with confocal microscopy. While signal was obtained from each of these slices, 2000 
kilo counts per frame for the controls and 15000 to 30000 for the AuNPs and Au-I-NPs. 
It was not easy to discern the nanoparticles from the background in specific regions due 
to quenching of the signal intensity and the lifetime of the fluorescence, which seemed to 
be prolonged due to the presence of gold. As such, a multiarea time lapse was performed 
on the confocal imaging (See Fig. 30). 
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Figure 30. This figure depicts the multiarea time lapse of the left lung for (A) control 
with very low auto-fluorescence, (B) control with some auto-fluorescence/bubbles, (C) 
Cy5.5-PEG-Au-I-Nps, and (D) Cy5.5-PEG-AuNPs.  
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Figure 30 seems to indicate that Cy5.5 nanoparticles distribute throughout the entire left 
lung. The signal of the probe thus seems to contribute to an increased background signal 
everywhere and as such explains why regional deposits were not found. In each of these 
images the threshold counts for Cy5.5 fluorescence was set to a minimum of 200 and a 
maximum of 1300. As such, these images were obtained at the same settings. One key 
difference that was observed in these images is that there is a significant increase in 
signal along the periphery of the lungs, where not even auto-fluorescence was observed 
in the controls. 
 
To further investigate and characterize the nebulizer system, micelles containing 
fluorescent probes were also imaged after nebulization and endotracheal delivery to 
show a divergence in regional intensity between the two. As such, we could characterize 
many features of the mouse nebulization system such as distribution in each lobe of the 
lungs (See Fig. 31) and even the previously utilized method (intratracheal delivery) 
versus nebulization delivery (See Fig. 32). 
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Figure 31. Confocal images of micelle dispersion in each of the 5 mouse lung lobes 
utilizing the mouse nebulizer system developed. As can be seen, the nebulizer system 
can deliver the micelles to every portion of the mouse lungs. 
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Figure 32. This is a side by side comparison of the mouse nebulization delivery 
technique compared to the previously performed method of intratracheal delivery. These 
are all the left lung and as can be observed results with the nebulization delivery were 
more repeatable and consistent then intratracheal delivery. 
 
As can be seen from figure 31, the micelles were delivered to all 5 lobes of the mouse 
lungs. Figure 32 on the other hand shows that intratracheal delivery does not often 
deliver an even distribution and is often inconsistent, which would make it difficult to 
reach statistical significance in any chemotherapeutic efficacy study. Figure 32 is the left 
lung as well, which according to the AuNP study performed herein (see Table 2), often 
gets 1.5 to 2 times the dose per square centimeter as any other lobe of the mouse lungs.  
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CHAPTER IV 
DISCUSSION AND FUTURE WORK 
The goal of this dissertation was to develop nanoparticle based theranostic agents for the 
treatment and diagnosis of cancer. As such, we have developed three means of treating 
radiologically and imaging via SPECT. We have also developed a fourth technique that 
could be synthesized similarly to the previously utilized radionuclides but can be used 
for optical imaging instead. This is because optical imaging is one of the best techniques 
for imaging cancer metastases in mice. We were also able to develop a mouse nebulizer 
system capable of delivering nanoparticles to the mouse lungs, whether they be 
radionuclides or modified chemotherapeutics. As such, this should enhance preclinical 
studies and further enhance testing of new drugs with a superior delivery method to 
intratracheal delivery.  
 
Regarding the AuNPs that were produced utilizing a modified Turkevich method. The 
RTCA system found that bare non-radioactive AuNPs have negligible or no cytotoxicity 
on SKBr-3 cells, in the short-term, as this study was only over a few days. A very high 
concentration of AuNPs were utilized and no noticeable difference in cell growth was 
detected among the different well cultures and controls. 
 
It is important to mention that 198AuNPs synthesized, along with the other nanoparticles 
synthesized, are considered protracted forms of irradiation and treatment like 
chemotherapeutics. The results from 198AuNPs experiments showed that radioactive 
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nanoparticles may be used as a potential strategy for the treatment of metastatic cancer 
since a small response was observed at 1000 and 1500 kBq. Future studies would need 
to be carried out to determine the proper therapeutic doses to a tumor. Otherwise, we 
question the effective internalization of 198AuNPS-HIV-1 Tat and further studies are 
required to assess if internalization was 1) limited by nanoparticle size, 2) by number of 
HIV-1 Tat cell penetrating peptide (CPP) per nanoparticle, 3) by radiation effects on cell 
cycle, or 4) lack of directionality of the HIV-1 Tat CPP against the cell surface. Other 
items to consider are the pharmacokinetics, clearance, and retention of nanoparticles via 
internalization into cells and whether the “cross-fire” effect mitigates the efficacy of 
using CPPs to bring radioisotopes closer to core components of the cell. One must also 
consider that AuNPs are believed to be internalized by some means of specialized 
endocytosis or micropinocytosis, so the degree of endocytosis at the concentration of 
HIV-1 TAT used may not be significant enough to cause significant differences.  
 
Furthermore, it may be beneficial to have the radionuclides on the cell membranes as 
aldehydes produced via lipid peroxidation on the cell membrane may be playing a key 
role in the DNA damage and senescence. Both ROS and radiation damage correlate with 
the damage induced by aldehydes as well except that aldehydes have been shown to 
have a preference for other lipids (to produce even more aldehydes) and the DNA (Vaca, 
Wilhelm, and Harms-Ringdahl 1988).  Aldehyde production has also been recently 
shown to be the potential key to radiation-induced senescence, which would be a major 
component in cancer treatment (Flor, Doshi, and Kron 2016). Nonetheless, we could 
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potentially observe a slight gain in cytotoxicity by the 198AuNPs-HIV-1 Tat when 
compared with 198AuNPs alone when pharmacokinetics and clearance are taken into 
consideration. 
 
This dissertation also verified that the aggregation of gold by iodine occurs faster than 
the formation of stabilized gold nanoparticles if the iodine/iodide is added too early in 
the synthesis procedure (Cheng, Dong, and Wang 2003; Daniel and Astruc 2004; Kim et 
al. 2012). Iodine/iodide is faster than sodium citrate at reducing the surface potential of 
gold clusters. Therefore, the kinetics of iodine/iodide-induced AuNP aggregation by 
reducing the surface potentials was investigated as a potential avenue for determination 
of the rate-limiting step, in order to prevent the rapid aggregation of gold nanoparticles 
after the addition of iodine/iodide. The rate-limiting step was determined to occur 
between 35 and 55 seconds. A threshold of 50 s was utilized to produce aggregation free 
synthesis of 125I-integrated AuNPs in our experiment. This was the time component for 
which iodine/iodide could be added without severely effecting the formation of the 
nanoparticles. The potential mechanisms of the synthesis and aggregation of AuNPs are 
presented in figure 33. 
 
We suggest that at the time range selected (~50 seconds), the gold nanoparticles were 
approximately midway stabilized in terms of their surface potentials, and that the 
addition of iodine caused the aggregation of smaller nanoclusters around the iodine to 
form the 125I integrated nanoparticle. This hypothesis is believed to be supported by a 
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distinct peak at approximately 95 seconds which could indicate that when gold 
nanoparticles are still undergoing the formation process, iodine could cause the 
aggregation of almost completely stabilized nanoclusters into larger than normal 
nanoparticles. Our results further indicated that at approximately 120 seconds the 
nanoparticles were completely formed, and thus iodine addition merely interacted with 
the surface of the nanoparticles, not significantly affecting the stabilization of the 
nanoparticles. This was substantiated by the color change in the solution to a wine-red 
color, which is characteristic of fully formed gold nanoparticles produced even in the 
absence of reducing iodide. In contrast, with the addition of iodine at any time after the 
addition of sodium citrate, the switch to a wine-red color was immediate, which would 
characterize rapid aggregation. 
 
The 125I integrated AuNPs were arduous to synthesize since instead of the concentration 
of iodide (I-) being equal to the concentration of sodium (NaI) in 1×10-5 M NaOH as 
performed before to obtain stability variations over time, the radionuclide used in the 
second synthesis was iodine (125I2) gas bubbled through 1×10
-5 M NaOH. Therefore, the 
125I integrated AuNP synthesis was significantly hindered by the limited amount of 
sodium, which is a potent stabilizing agent. The reduced quantity of Na, made the iodine 
injection at a time where the AuNPs were midway stabilized a key component in the 
prevention of iodine-induced aggregation (Polte et al. 2010). Another hypothesis is that 
the increased concentration of sodium prevents long chains or clusters of polyiodides or 
polyiodines from forming. This was supported by a second observation in which a 5 mCi 
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concentration of iodine in 1×10-5 M NaOH was utilized and found difficult to use even 
when readjusted to the concentrations used in the 2 mCi samples, potentially indicating 
that the clusters were already formed. Another item to consider is that the 
electronegativity of all isotopes of an element may not be the same; especially for a 
radioisotope that may have the propensity to increase or decrease its electronegativity to 
compensate for emissions during decay. Changes in electronegativity between isotopes 
have been observed using NMR and chemical reactions with carbon and hydrogen 
isotopes (Gombler 1982; Wolfsberg 2002).  Under such conditions, it would thus seem 
plausible that 125I has a different electronegativity from other iodine isotopes. When a 
particle is excited and about to decay it is assumed that the nucleus is in flux, therefore 
there is bound to be fluctuations in how the nucleus holds on to orbiting electrons as the 
localization of protons in the nucleus changes to counteract changes in the electron 
cloud.  
 
Making the iodine/iodide indistinguishable from background or noise brought about by 
the sheer quantity of other elements in the nanoparticles, proved to be difficult. 
However, centrifugation with and without a nanopore filter showed that the iodine was 
indeed associated with the nanoparticles and not free in the solution. The relative 
stability at high temperatures and lack of noticeable aggregation with this protocol in 
contrast to addition of iodine in the beginning of synthesis or after synthesis would also 
seem to suggest different types of interactions, which are discussed in this paper and 
hypothesized in figure 33. However, this process will hopefully be further improved and 
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repeatability further enhanced with microcontrollers, which were being designed for 
211At incorporation into AuNPs. 
 
 125 
 
 
Figure 33. Proposed mechanisms of integration into gold nanoparticles occurring via collisions of iodine induced citrate 
displaced regions. Collisions could potentially occur between averaged sized nanoparticles or smaller nanoparticles on larger 
nanoparticles. The lines depict interactions with neighboring molecules. Reprinted with permission (Clanton et al. 2017).
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The TEM images revealed clusters of aggregated AuNPs, possibly bonded together by 
iodine (see Fig. 26). Many of the nanoparticles were ovoid instead of spherical as well. 
This suggests the formation of gold nanoparticles to be a kinetics based situation with a 
threshold at which there is a small range of partially formed nanoparticles with a small 
variance in size. This data seems to suggest that those nanoparticles that are on the upper 
scale of that range could collide and create larger than average nanoparticles; this is 
especially true when iodine/iodide reduces the surface potentials of these nanoparticles, 
and as a result less energy is needed for collisions to occur. One of the most interesting 
aspects of figure 26 that could support this, is that the nanoparticles with the darkest 
cores at the center of the image, are the most aggregated or “attracted” to each other. 
 
AuNPs have varying degrees of effectiveness in targeting tumors depending on their 
size. This phenomenon exists because there is a slow accumulation of the AuNPs in the 
tumor from circulating blood; this requires AuNPs to be small (~20 nm), given that they 
will be cleared more slowly from the blood than larger nanoparticles (~80 nm) which are 
more effectively cleared by the liver and spleen than the smaller nanoparticles (Zhang et 
al. 2009). Their biodistribution substantiates the previously discussed assessment that 
nanoparticles can target phagocytic cells since this uptake or clearance seems to stipulate 
that the reticuloendothelial system (also called the mononuclear phagocyte system or 
macrophage system) is involved (Mkandawire et al. 2015; Chang et al. 2008). With the 
mentioning of macrophages, the author would also like remind the readers of when 
Virchow first noticed the infiltration of inflammatory cells into tumors and that certain 
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subsets of cancer cells have been shown to express or present macrophage antigens as 
well (Lazova, Chakraborty, and Pawelek 2011; Powell et al. 2011; Shabo and Svanvik 
2011). This presence of phagocytic cells in a tumor population just like those in the 
spleen and the liver would seem erroneous to ignore when it comes to AuNP retention 
within the neoplasm.  
 
 Furthermore, even though a small amount of the nanoparticles may go to the kidneys, 
conclusive evidence of cytotoxicity has not been shown in this organ or tissues, such as 
the liver. Even with low to moderate cytotoxicity being possible, excretion does occur 
slowly over time. Therefore, moderate inflammation and apoptosis should be rather short 
lived but further investigation would be prudent (You et al. 2014; Patra et al. 2007; Cho 
et al. 2009). Cytotoxicity would most likely be dependent on the size and the ability of 
nanoparticles to leave vesicles or interfere with transporters. Since the 20 nm AuNPs 
have longer retention times in the blood, they would be expected to show longer mean 
residence times, longer terminal elimination half-lives, and lower total body clearance, 
which should result in increased levels of accumulation in the tumor due to EPR (Zhang 
et al. 2009). 
 
 The actual concentrations retained in each tissue may fluctuate widely as the size 
increases from 1 nm to 80 nm diameters. For example, 50 nm, the size of spherical 
viruses with the highest transduction activities, has also been shown to be the diameter at 
which NPs are most highly up-taken by mammalian cells (Chithrani and Chan 2007). 
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Therefore, further assessment would need to include endocytosis, exocytosis, clearance 
from the blood, and uptake into target cells of interest to determine the appropriate 
therapeutic diameter for the nanoparticles. Although the nanoparticles in this experiment 
are less than the optimal size for cellular intake, based on the previously stated studies 
they should reside in the blood considerable longer (less uptake by spleen or liver and 
more leakage into the neoplasm), potentially increasing chances of targeting CTCs and 
sites of metastasis, which would be a more appropriate approach to avoid complications 
from treatment. Once these are taken into consideration and their values found, the 125I 
integrated AuNPs can be assessed for the concentration needed to obtain similar 
therapeutic results to other treatments, or in other words its relative biological 
effectiveness.  
 
While 125I has been used routinely for seed brachytherapy, it is important to note that the 
radiotoxicity of 125I and other Auger electron emitters have been shown to have a large 
dependence on their subcellular distribution and thus seeds are an inefficient means of 
utilizing these isotopes (Narra et al. 1992). Using centrifugation and redistribution, we 
have been able to accomplish 90-100 µCi within a 100 µl solution. This would equate to 
3,700,000 Bq and if each decay equates to 106 cGy within a 2nm radius, as previously 
mentioned, then this would become 3,922,000 Gy potentially distributed within 7400 µm 
or 0.75 cm if uniformly dispersed. However, we know this is not true and nanoparticles 
will mostly be taken up by the more phagocytic cells. This contrasts with 125I 
brachytherapy seeds, which are prescribed at 145-190 Gy over 150 seeds with 
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approximately 0.4 to 0.5 mCi of activity each.  However, not all tumor treatments 
require 150 seeds to be implanted since. The activity and prescription of seends would 
be determined to fit the clinical context. These seeds having a titanium coating blocking 
the Auger electrons and thus are only obtaining exposure from gamma rays. Another 
major difference between these liquid brachytherapy nanoparticles versus the typical 
seed brachytherapy is that these nanoparticles can be delivered at different intervals like 
chemotherapy and in conjunction with other treatments. Thus 600 injections of the 
nanoparticles may appear to be needed but this would be an erroneous comparison since 
the radiotoxicity of 125I appears to be dependent on subcellular distribution and Auger 
electrons, which can’t be accomplished with seeds as they are now. However, seeds do 
have an advantage in spatial positioning and non-dependence on a universal target, 
which to this date still hasn’t been identified. 
 
211At was easily added at the very beginning of the synthesis, which is probably due to 
its lower electronegativity. Before, considerable cytotoxicity studies can be performed a 
means of automation to produce 211At is needed. Then, long-term studies would need to 
be performed in vivo to ascertain whether the well-known effectiveness of targeted 
therapies using 211At overcome any toxicity and long-term effects in the body, which 
have been poorly quantified. 
 
Cy5.5-PEG-AuNPs and Cy5.5-PEG-Au-I-NPs both had fluorescent signals even though 
they were significantly quenched by the AuNPs. Since this quenching seems to depend 
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on distance, future studies would need to look at using different kDa sizes for the PEG 
chains. While not significant, it does appear that Au-I-NPs put off a stronger fluorescent 
signal, which is strange since iodine can also quench the fluorescent signal. One 
hypothesis that will need to be examined is that iodine may compete with the thiol 
groups on PEG in binding to AuNPs. As such, there may indeed be more quantities of 
free Cy5.5-PEG-thiol that is contributing to a higher signal intensity.  
 
The mouse nose-only nebulization system was effective at delivering fluorescent probes 
to the lungs of the mice. Dr. Wooley’s lab has been using the system for a couple months 
now and they have found that they get more of their chemotherapeutic drugs delivered to 
the lung metastases using this method and repeatedly have obtained more statistically 
significant results. Since their mice are immunosuppressed and very fragile they were 
previously losing one in four mice every time they used the previous intratracheal 
delivery. They have not lost a single mouse since incorporating my nebulization system.  
In the future, further development of the system will occur such as incorporation of a 
removal port to recollect some of the nebulized drugs that don’t make it to the mouse 
lungs, replacing the anesthesia gas with an O2/CO2 mixture that will increase the 
breathing rate and instead using anesthesia injections, and enhancement of the enclosure 
system to further prevent leakage of drug or imaging probe nebulized. 
 
Furthermore, the delivery of long-lived radionuclides, like 125I, to the lungs would be the 
next pursuit as well since short-lived radionuclides like 18F may not be possible with this 
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technique due to the multiple doses that may be required and the limited amount that can 
be delivered due to regulations. However, recollection and redelivery may surpass this 
limitation. Right now, dimerized paclitaxel and brush polymers are also being 
investigated with the nebulizer with some of the imaging results presented herein. 
 
The major component that will need to be investigated further is the co-localization of 
tumor and AuNPs. Unlike vascular delivery that results in AuNP removal from 
circulation and retention in the tumor within three days, signal was still seen throughout 
the entire lungs, including the tumor without much evidence of a biased signal toward 
the tumor. Since other nanoparticles, like brush polymers, can sit in the lungs for 
months, this may be a unique characteristic of the lungs itself. A long-term study would 
need to be performed to discern if the EPR effect occurs in the lungs. Furthermore, drugs 
and imaging probes may need to be developed that only work once they reach the tumor. 
This is what occurs with the dimerized paclitaxel as it only becomes active in the 
presence of glutathione and the brush polymers only break down in the presence of 
proteases (both increased in the tumor microenvironment). My thoughts are to use gold 
again but this time completely quenching the fluorescent signal. However, the 
fluorescent probe will now have components sensitive to proteases, glutathione, or 
acidity (limited since a significant amount of the probes reach the stomach) that cleave 
the fluorescent probe and/or drug in the tumor microenvironment. This may also be 
accomplished with my previous idea of inoculating the tumor with microbes and using 
AuNPs coated in microbial substrates to break down the substrate and free the drugs and 
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fluorescent probes. For radionuclides for therapy, I am suggesting a degradable shell that 
captures most of the emissions until the presence of the tumor microenvironment breaks 
down that shell, thus allowing macropinocytosis and/or the emissions to interact with 
and cause damage to the cell.  
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CHAPTER V 
CONCLUSIONS 
 
There is potential in creating novel cancer treatments by combining Targeted 
Radionuclide Therapy (TRT) and nuclear nanotechnology. As such, the use of nuclear 
nanotechnologies, where the nanoparticle core can serve as complex carriers of not only 
radionuclides but chemotherapeutics as well. However, with radionuclides alone this 
would yield new radiography agents with potentially higher safety and efficacy profile 
than those currently used clinically. Even combining radiosensitizing chemotherapeutic 
drugs with radioisotope integrated AuNPs would open a completely new avenue of 
research that has only recently began to be investigated (Zhao, Zhou, and Li 2016). 
 
In terms of 198Au and (198Au-197Au) we could determine that it is quite feasible to 
produce nanoparticles with a therapeutic quantity of radionuclides. This method itself 
was shown to be capable yielding a good mono-dispersed population of AuNPs with an 
average diameter 32.9 nm. SKBR3 tumor cells were targeted with HIV-1 Tat cell 
penetrating peptide as an initial proof of principle. While the results didn’t necessarily 
show increased efficacy an in-vivo model may show enhanced attachment to 
micrometastases versus nontargeted nanoparticles. The cell growth results showed a 
clear dependence on the activity administered, with response appearing to only occur 
above 1000 and 1500 kBq per well, for both functionalized and non-functionalized 
198Au, at least within the time frame measured.  
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Regarding the iodine integrated AuNPs. Due to the strong interactions between 125I ions 
and gold, as well as iodine’s ability to displace citrate groups stabilizing the surfaces of 
the gold nanoparticles, it is proposed that iodine will be preferentially added to the sides 
of the nanoparticles that are not completely stabilized by citrates during synthesis. 
Consequently, the gold nanoparticles will aggregate in areas where iodine has displaced 
the citrates; this conclusion can also be inferred by the figures produced by Figuerola 
and colleagues (Figuerola et al. 2009). As a result, a “layering” effect potentially occurs 
as the nanoparticles are forming. If this is true for normal conditions in which the 
nanoparticles are already formed and coated, then it is applicable that collisions will also 
occur where iodines (I2) and/or iodides (I
-) are being integrated into the matrix of the 
forming nanoparticles. This would hypothetically create layered materials or ovular 
nanoparticles as previously suggested in figure 26. Whether iodine atoms get re-shuttled 
to the surface is questionable but it is suggested to be highly unlikely if polyiodides 
and/or polyiodines are formed and integrated into the gold nanoparticle structure in 
layers. There is no known literature precedence that would suggest that impurities can be 
re-shuttled to the surface in other studies. Since inclusion of iodine could potentially 
result in a more negative nanoparticle core, a larger concentration of reducing agent 
seems required to compensate. However, if the concentration of reducing agent is fully 
maximized or there are a maximum number of citrates on the surface of the 
nanoparticles, then increased stabilizing agents such as sodium are required to prevent 
aggregation. This conclusion was supported by the results obtained from our research.  
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This study demonstrates that there is indeed a kinetics process dominating the formation 
of gold nanoparticles. As such, future work involving the integration of AuNPs with 
radiohalogens will require careful attention to kinetic factors. Furthermore, this study 
also demonstrated the rapid synthesis of gold nanoparticles integrated with 125I for 
diagnostics and therapeutics that have no statistically significant leaching from the 
nanoparticle. Subsequent testing showed that ionic solutions, such as boron tri-fluoride, 
were unable to remove the iodine from the gold nanoparticles. Consequently, there 
should thus be a higher uptake of the radionuclide in desired target tissues (Smith and 
Oates 2004). 
 
Continuing with this concept of combining halides with AuNPs were also able to 
accomplish the combination of 211At. This combination would potentially be a very 
effective route of treatment for several types of tumors, especially renal cancers and 
hepatocellular carcinomas (Paciotti, Kingston, and Tamarkin 2006). However, 211At 
seemed to have no issue being added to the nanoparticles at least at the concentration of 
gold used in synthesis. This could be due to weaker electronegativity and as such a lower 
capability of causing an aggregation of nanoparticles during synthesis. 
 
Combining these two ideas, radionuclides with AuNPs, allows for a treatment that not 
only helps prevent metastasis and proliferation via mitochondrial fusion but could also 
lead to a new paradigm in which the genetic information of both the mitochondria and 
nucleus are targeted by re-positioning them adjacently. With the addition of 
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functionalizing substances, certain apoptotic pathways can be targeted as well (Medine 
et al. 2011). Therefore, radionuclides integrated with AuNPs are applicable to treatment, 
due to their multi-faceted approach in preferentially targeting neoplastic cells with 
fragmented mitochondria or increased energy consumption. Furthermore, short ranged 
high-LET radiation along the cell membranes would be very powerful in inducing 
aldehyde formation, which would be very important for inducing senescence of the 
cancer stem cells (Zhang et al. 2016).  
 
A main component of utilizing these radionuclides (I-125, Au-198, and As-211) is that 
they are theranostics; capable of being used therapeutically and diagnostically (imaging). 
The most promising feature of radionuclide integrated AuNPs, however, lies in the 
potential to image neoplasms while treatment is carried out. In vivo imaging is an 
important tool for preclinical studies of neoplasms and presently with particular interest 
on lung function and disease. This is because lung cancer is the leading cause of cancer-
related deaths for both men and women throughout the developed world (Purandare and 
Rangarajan 2015). Therefore, to show that AuNPs were efficacious in delivering 
therapeutics (radionuclides or chemotherapeutics) and diagnostic probes (radionuclides 
or fluorescence) I was also able to develop a mouse nebulizer bed system with 3D 
printing technology. The nebulization system was more effective at evenly distributing 
nanoparticles throughout the entire lungs. This distribution was markedly different than 
the typical intratracheal delivery. Nebulization was also drastically safer resulting in zero 
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deaths during studies versus the approximately 1 in 4 deaths observed with every 
intratracheal delivery with these immunosuppressed mice. 
 
Overall, the goal of this dissertation and doctorate work was to show the development of 
nanoparticles to be used for theranostic purposes, to deliver these compounds to the 
lungs of mice utilizing an aerosolizing modality, and to show what techniques could be 
used to characterize the compounds delivered to the mouse lungs qualitatively and 
quantitatively. These tasks were accomplished effectively and can be used for starting 
preclinical imaging and lung treatments at any facility.  
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